Vision | Expertise | Technology | Community

Transcription

convergence
vision | expertise | technology | community
A
t the University of Chicago Cancer
Research Center, our mission is
to understand, cure and prevent each of
the scores of diseases we collectively call
cancer. We pursue this goal by promoting
collaboration among a diverse and dedicated
team of outstanding laboratory scientists,
caregivers, clinical researchers and trainees.
These partnerships help us develop solutions
tailored to the complexity of individual
cancers and the unique needs of each
patient. Our faculty and staff are dedicated
to mentoring and inspiring the investigators
of tomorrow while providing superior care
to the people of today.
1-2
Letters:
From the Director
From the President of the Foundation
and the Director of the Foundation
3
Introduction:
Divergence and Convergence
5
Vision and Convergence
9
13
16
19
Convergence of Expertise
25
Foundation Boards and Auxiliaries
28
Financials
Technology and Convergence
Community and Convergence
Benefactors
T
his annual report is retrospective and prospective. It both reviews our activities in the
2004-2005 fiscal year and explains how these efforts will shape our future. For the
past 20 months, our members, staff, and supporters have engaged in a collaborative
effort to design and implement a new strategic plan. This plan will help us take advantage
of today’s numerous opportunities in medical discovery, advance the integration of the
University’s wealth of resources, and enable us to enhance cancer care and bring the benefits
of breakthrough science to our patients.
The driving dynamic of this plan is convergence. It describes how we will promote
collaboration, share our resources, and focus our endeavors in the development of new and
better ways to prevent, diagnose, and treat cancer. The construction of the new Center
for Biomedical Discovery is an example of convergence at work. The new building will be
an integrated and richly creative environment that will facilitate interaction among our
members and their colleagues in the biological, physical, and social sciences. It will engender
discovery at the intersections of diverse disciplines, perspectives, knowledge, and expertise.
I am thankful to my many colleagues who have employed their talent, wisdom, and
dedication to make spectacular advances in cancer research. Their success in securing
competive research grants demonstrates their excellence, as our research funding base has
increased to $104,658,018. I regret that the abundance of the successes of my colleagues has
made it impossible to include all the highlights of this year’s research in this report. We have
space for only a small sample of their extraordinary achievements.
I am also thankful for the support of our friends in the community and especially the
assistance of the University of Chicago Cancer Research Foundation and the participation
of other donors and groups. These supporters are vital to our ongoing success.
In addition, I am thankful to the University for its faith in our work and its renewed
emphasis on cancer research and care. Energized by this support, we are eager to confront
tomorrow’s challenges.
As you read this report, please be sensitive to the importance of your contributions.
We accomplish none of our achievements in isolation. They all demonstrate the power of
convergence.
Respectfully,
Michelle M. Le Beau, PhD
Professor of Medicine and Human Genetics
Director, University of Chicago Cancer Research Center
Director, Cancer Cytogenetics Laboratory
convergence |
A Message from the Director o f t h e U n i ve r s i t y o f C h i c a g o Ca n c e r R e s e a rc h Ce n t e r
| UCCRC Annual Report 2004-2005
Consequently, we are enormously excited about the future and confident in our ability to
relieve some of the burden of cancer on our patients, their families, and our communities.
This is a time of great optimism and hope, and I am thankful for the many people who have
made this bright future possible.
T
Ruth Ann Gillis McGuinnis
he past year has been one of reevaluation, renewal, and reformation. The University
of Chicago Cancer Research Foundation (UCCRF) has been busy preparing itself
for the electrifying times that lie ahead. This is a climactic moment in the history of
cancer research. New knowledge and technologies offer the promise of enormous progress.
Therefore, it is time to intensify our efforts, seize the opportunities, and reach for new
heights above and beyond anything accomplished in years past. We will remain the Cancer
Research Center’s faithful, enthusiastic and effective partner.
In her first year as Director of the University of Chicago Cancer Research Center, Dr.
Michelle Le Beau has implemented a comprehensive strategy to encourage greater
collaboration among researchers, attract new talent to the University of Chicago, and
provide its members with new assets to support their vital work transforming cancer
prevention, diagnosis and care. At the UCCRF, we are ready to participate actively in the
implementation of this agenda for action.
Mary Ellen Connellan
That is why we are especially pleased at the Foundation record fundraising in Fiscal Year
2004-2005 when we contributed $1,900,011 to the UCCRC. This amount exceeds last
year’s total by more than $135,000. We are all grateful to our dedicated members and other
generous donors who have made this extraordinary success possible.
A Message from the President and the Director
The Cancer Research Center has put these contributions to good use. We see the impacts of
the Foundation’s giving at work throughout the University. Our donations – large and small
– have enabled the purchase of state-of-the-art equipment, enhanced laboratory facilities,
funded recruitment of top faculty and fellowships for young scientists, and generated
innovative research by many of our most distinguished researchers. These scientists rely on
this essential support because it provides them with the freedom necessary to pursue their
most visionary investigations and explore new frontiers in cancer research.
At the same time, we recognize that we must redouble our efforts and maximize every
opportunity to increase our contributions in support of the UCCRC’s ambitious campaign
to strengthen its operations. Staffing and equipping laboratories in the Center for Biomedical
Discovery now under construction, for example, is an important and immediate challenge.
This annual report makes a strong case for increased participation, because it demonstrates
the power of our participation and the worthiness of the programs we support. We hope it
will also make you proud of your role in this success and inspire you to become even more
involved in the Cancer Research Center’s brilliant future.
We thank each and every one of you for your wisdom, your commitment and your
generosity.
Sincerely,
Ruth Ann Gillis McGuinnis
President,Director,
The University of Chicago The University of Chicago
Cancer Research Foundation
Divergence and Convergence
C
ancer is not a disease.
It is scores of divergent diseases sharing a common origin: mutations in genes that enable aberrant cell growth.
Nothing about this transition is simple. It involves countless chromosomes, genes, proteins, cells, and
processes and innumerable, cellular, genetic, and chemical interactions performed at the molecular level.
It is a process characterized by divergence and wrapped in mystery.
Successfully unraveling the mystery of this complex, divergent group of diseases and helping cancer
patients survive their disease requires a diversity of expertise, technologies, and perspectives. Researching
abnormal cell growth demands the integration of resources, disciplines, and sciences and the collaboration
of experts throughout the University and across the globe. The tradition of the individual researcher
working long, isolated hours at the laboratory bench is passing. The hours are still long, but they are no
longer lonely. Seeking better cancer cures and enhancing patient care call for the participation of medical
professionals, patients, and the community of donors.
Cooperation and Collaboration
The need for a diversity of perspectives and expertise is why the UCCRC’s pioneering researchers
emphasize multidisciplinary approaches and value cooperation and collaboration. Our modus operandi
is to focus on building bridges, literal and figurative, that connect laboratories to clinics, strengthen the
bonds between the University and communities, and bring departments, institutes, organizations, and
facilities together.
Over the years, the UCCRC has welcomed biologists, surgeons, radiologists, oncologists, pathologists,
biochemists, radiation oncologists, epidemiologists, statisticians, physicists, chemists, psychiatrists,
sociologists and geneticists intent on bringing new expertise and knowledge to enhance our understanding
of cancer prevention, diagnosis, and treatment. Today, we are expanding our reach to encompass an even
broader range of knowledge, information, and skills and ensure better care and quality of life for cancer
patients.
convergence |
Wrapped in Mystery
Normal genes trigger the processes that signal superfluous or damaged cells to self-destruct and make way for new
healthy ones. Abnormal genes disrupt this critical aspect of the natural lifecycle of cells creating cancerous cells.
These aberrant cells do not die even when they can no longer perform vital functions as effectively as their healthy
counterparts and, in some cases, they acquire functions that their normal versions do not have. Furthermore, they
multiply rapidly, displacing normal cells and invading healthy tissue. Too often, the result is organ failure and
death.
Convergence and Our Mission
Convergence is fundamental to our mission, and it is evident in practically everything we do. It energizes
our vision of the future and pervades our new strategic plan, which describes new programs and policies
designed to promote convergence. The physical designs of our facilities – in place or under construction
– also will advance this objective. Most of all, convergence helps us enhance cancer care and perform
research that will serve future generations.
Vision, Expertise, Technology, and Community
The annual report for 2004-2005 focuses on this emphasis and how it shapes our planning, advances
our research, and fuels breakthrough discovery. It explores how we encourage interaction for the benefit
of cancer patients around the world and how convergence informs our vision, integrates our expertise,
influences our use of technology, and strengthens our relationship with the community.
Vision and Convergence
C
Evolution and Evaluation
The UCCRC has sustained this level of success by continually examining and strengthening its programs.
It has also periodically intensified this process of evolution and evaluation to address new challenges and
take advantage of fresh opportunities. Currently, the Center is engaged in the most extensive process of
reinvigoration and reinvention in its history. This year, the UCCRC developed a strategic plan to guide
and help advance the University’s ambitious attempt to integrate the University’s cancer research efforts,
maximize its resources, and employ them more effectively.
One of the goals of this plan is to expand the breadth of the UCCRC and enhance its resources in cancer
prevention and control. This will advance our objective to gain National Cancer Institute designation as a
Comprehensive Cancer Center, which will more accurately reflect the depth and breadth of our research
program.
Tactics for Change
The Strategic Plan outlines tactics designed to:
• Strengthen our scientific programs;
• Enhance the translational component of each program;
• Promote multidisciplinary and interdisciplinary research;
• Develop multidisciplinary, disease-specific working groups;
• Increase the participation of basic scientists from all disciplines;
• Upgrade existing shared facilities and create new ones where necessary;
• Provide researchers with enhanced information technology resources; and
• Expand our programs in cancer prevention and control.
convergence |
Dr. Ultmann also understood that effective cancer research is cross-disciplinary, bringing together investigators
representing a diversity of perspectives and expertise. The UCCRC became the fulfillment of his dream of an
organization that would unite some of the world’s finest researchers in order to focus their efforts on basic, clinical
and translational cancer research. “Translational research” transforms laboratory findings into the next generation
of cancer therapies and potential cures. Today the UCCRC is comprised of approximately 190 clinical and basic
scientists working together to discover new insights into cancer’s causes, characteristics, and cures. It has earned a
global reputation for excellence, innovation and a commitment for attacking cancer from every angle.
ollaborative inquiry is the hallmark of the University of Chicago Cancer Research Center. Dr. John E.
Ultmann, the driving force behind the creation of the UCCRC and its first Director, was an outspoken
proponent of multi-disciplinary treatment of Hodgkin’s disease and other lymphomas, which are cancers
of the lymphatic system. His innovative approach to treatment was instrumental in dramatically reducing the high
mortality rates in this group of cancers. Death rates for Hodgkin’s disease, for example, have dropped by 60 percent
since the 1970s. Cancer treatment at the University of Chicago continues to emphasize this multidisciplinary
approach. Teams of medical oncologists, radiation therapists, surgical oncologists, geneticists, pathologists, and
others meet to consider every patient’s case and recommend individualized treatment plans.
The plan will enable us to sharpen our focus on three “Discovery Hot Spots”: Metastasis, Cancer Prevention
and Control, and Drug Discovery. These “Hot Spots” have enormous potential for reducing cancer death,
mitigating its consequences, and lowering incidence for all types of cancer. Special working groups are
evaluating existing efforts and developing plans to enhance our programs in these areas.
Three “Hot Spots”
Carrie Rinker- Schaeffer, PhD, and Charles Brendler, MD, head the Metastasis Working Group. Metastasis is
the migration of tumor cells from one part of the body to another where they lodge and ultimately grow into
a detectable tumor. It is the leading cause of cancer death. Most research, however, centers on the treatment of
primary cancers and fails to consider metastasis as a distinct entity with its own dynamics. That is the mission
of the new Ludwig Center for Metastasis Research which will enlist basic and clinical researchers in a uniquely
targeted effort. Geoffrey Greene, PhD, Virginia and D.K. Ludwig Professor, and Ralph R. Weichselbaum,
MD, Daniel K. Ludwig Professor, and Chairman, Department of Radiation and Cellular Oncology, who
have expertise in both basic and clinical research, will serve as interim co-directors of the Center. We plan to
recruit an internationally recognized scientist to be the Center director and two or three other scientists who
will integrate new and existing expertise on metastasis to create a hub of research excellence focused on this
critical issue.
David Meltzer, MD, PhD, and Christopher K. Daugherty, MD, are developing the Cancer and Social
Sciences Working Group to help address the second “Hot Spot,” cancer prevention and control. This type of
research incorporates a wide range of possible investigations from the genetic, environmental, and behavioral
determinants of cancer susceptibility to chemoprevention and early detection. Research demonstrates that we
could prevent more than half of all cancer cases through the successful application of existing knowledge to
modify behavioral risk factors for cancer. Effective research in this promising area requires the cooperative
participation of clinicians, biologists, chemists, geneticists, and behavioral and social scientists.
The drug discovery “Hot Spot” will build upon one of our greatest strengths, strategies for the identification,
development, and evaluation of effective therapies that stem from our growing knowledge of the minute
world of individual cells, genes, chromosomes and proteins. Multidisciplinary teams of clinical investigators
representing Medical Oncology, Radiation Oncology, Pathology and appropriate surgical specialties analyze,
test and develop experimental therapeutics and procedures. These groundbreaking efforts allow us to provide
our patients with advanced treatments that are often available nowhere else. M. Eileen Dolan, PhD, and Dr.
Geoffrey Greene lead the enhanced drug discovery program outlined in the strategic plan.
Three Working Groups
The UCCRC has also established three disease-specific working groups, which are studying women’s cancers;
lung, head and neck cancers, and gastrointestinal cancers. We believe that grouping individuals around specific
disease sites will facilitate and encourage translational research, and produce extraordinary results. Co-Leaders,
with expertise in basic, clinical and population-based research, are responsible for these working groups.
Many of the researchers working on these issues will ultimately be located in the Center for Biomedical
Discovery (CBD). This extraordinary asset will facilitate the achievement of our vision. On October 17, 2005,
the University broke ground on this $162.5 million research building, which will be the tallest structure
on campus. The 333,760-square-foot building will house more than 700 investigators, technologists and
administrative personnel engaged in or supporting state-of-the-art translational research. The building will
have space for research teams in the Institute for Molecular Pediatric Sciences. These researchers will try to
learn why diseases affect some children and not others, and why treatments work on some and fail on others.
Center for Biomedical Discovery
Several floors of the building will be devoted to cancer research, including the home of the Ludwig Center
for Metastasis Research. The UCCRC will have eleven dedicated laboratories for our investigators—many
of them new recruits—who will engage in addressing the research priorities outlined in the Strategic
Plan. Common areas and bridges will physically connect our researchers to their colleagues working in
the biological, physical, and social sciences. The building will be adjacent and connected to the Center
for Integrative Science, which is the home of the Ben May Institute for Cancer Research. Scientists
representing the breadth of scientific inquiry will locate their labs and offices in the new building.
Placing our researchers in close proximity to their colleagues working in the biological, physical, and
social sciences, the CBD’s richly creative environment will be an incubator for realizing the potential of
the exciting approaches outlined in our strategic plan.
The CBD will be another manifestation of the philosophy of convergence that informs our history,
harkens back to our beginnings, and drives the implementation of our Strategic Plan. This new facility
will not only be a hub of productive, multi-disciplinary research but will also serve as a monument to the
collaborative research that is at the heart of our mission.
7
Seeking Cancer Cures On All Fronts |
New Laboratories
Convergence of Expertise
S
Discovery as a Cooperative Effort
Discovery is a cooperative effort, and many of the UCCRC’s significant advances involve multiple
investigators and technologists. Our labs are not places for individual inquiry, but small communities
where investigators and technologists share common missions. Often these communities come together
to address promising avenues of research.
For example, a broad, interactive, and multidisciplinary group of investigators with strong records in
research in cancer genetics, cell growth and survival, experimental drug development, and state-of-theart blood-related cancer research, collaborate to discover treatments for leukemias and lymphomas that
remain major challenges. This group includes, among others, Michael J. Thirman, MD; John Anastasi,
MD; Wendy Stock, MD; John Crispino, PhD; Michelle M. Le Beau; PhD, Stephen J. Kron, MD, PhD;
Richard A. Larson, MD; Koen van Besien, MD; and Amittha Wickrema, PhD.
Expanding and Crossing Boundaries
Often such collaboration crosses the boundaries separating traditional disciplines. Dr. Geoffrey Greene,
and Milan Mrksich, PhD, Professor of Chemistry, work closely together in research at the interfaces of
chemistry, biology and materials science. Their research, for example, focuses on the identification of small
molecules that inhibit proteins essential to the growth and/or survival of malignant breast cancer cells.
convergence |
Consider the discovery of the drug Gleevec, which some believe to be the most promising cancer therapy of our
time. Although the Food and Drug Administration (FDA) approved the drug for sale in May 2001, the process of
discovery began more than 40 years ago when Dr. Peter Nowell reported that patients with chronic myelogenous
leukemia (CML) consistently had a specific chromosomal alteration. The full implications of this discovery did not
become clear until 1973 when Janet D. Rowley, MD, the University of Chicago Blum-Riese Distinguished Service
Professor of Medicine, demonstrated that pieces of chromosome 9 and chromosome 22 had exchanged places. This
translocation produces a cancer-causing protein called BCR-ABL. Dr. Rowley’s discovery prompted 27 years of
additional research in America and Switzerland that ultimately produced Gleevec, which treats CML by inhibiting
BCR-ABL. Thus, one of the greatest cancer advances of our time required dozens of investigators and four decades
of research before it could become readily available to help cancer patients.
ir Isaac Newton’s famous quotation – “If I have seen further it is by standing on the shoulders of Giants”
– reminds us that scientists rarely make great discoveries in isolation. The vast majority of research
breakthroughs are the products of hard work and the convergence of numerous insights by many creative
investigators. Today, the explosion of information and the availability of increasingly sophisticated equipment
and technology necessitate even greater interaction among scientists. The UCCRC has made significant advances
in cancer research, because our scientists have welcomed the fertile sharing of ideas with their colleagues at the
University of Chicago and with others across the globe.
The Convergence of Disciplines
Cancer’s growing complexity also encourages the convergence of existing disciplines to create new ones.
Pharmacogenomics is the integration of genetics, pharmacology, and medicine to analyze how a person’s
genetic makeup influences his or her body’s response to drugs. This information is invaluable in enhancing
the effectiveness and safety of cancer drugs. M. Eileen Dolan, PhD and Mark J. Ratain, MD, the Leon O.
Jacobson Professor of Medicine, and their colleagues have worked together to make the UCCRC a world leader
in this promising new field.
Dr. Dolan used pharmacogenomics to develop an innovative approach to study effectiveness and toxicity
of a class of cancer drugs called platinating agents. (Platinating agents alter the DNA of abnormal cells in
order to block their proliferation.) One drawback to genetic studies assessing the impact of cancer drugs
is that researchers obviously cannot give an anticancer drug to test its impacts on healthy family members
who do not have cancer. Therefore, they cannot directly assess the heritable variables that determine how
the drug will affect individuals. Dr. Dolan has developed a comprehensive, unbiased model to elucidate how
genetic differences alter the effects of anticancer agents. She used cell lines collected from 692 members of 55
multi-generational families to identify genetic traits related to pharmacodynamic effects. This comprehensive
approach makes it possible to identify the impact of any gene without having to make a priori assumptions
about specific classes of genes.
Dr. Mark Ratain and Federico Innocenti, MD, PhD, use genetic analysis to identify patients at high risk for
life-threatening toxicity from irinotecan, one of the few drugs effective for cancers of the colon and rectum.
This work led directly to the insertion in the drug’s product label of a “Warning” to inform physicians that
genetic testing may call for a reduction in dosage and consequent toxicity. In addition, the University is in the
process of identifying one or more companies that may be able to commercialize the test so that physicians can
use this discovery to guide treatment choices and protect patients. Dr. Carrie Rinker-Schaeffer, a nationally
recognized leader in metastasis research, and her laboratory identified a unique gene that specifically inhibits
prostate cancer growth. She and her colleagues are currently investigating how this MKK4 protein induces
tumor dormancy of cancer cells.
Convergence and Cancer Clinical Trials
Dr. Ratain has also collaborated with Walter M. Stadler, MD, in a clinical trial to study the efficacy and safety
of an experimental drug, sorafenib. They demonstrated the drug’s usefulness in treating kidney cancer. These
significant findings led to an international Phase III clinical trial and the recent filing of a New Drug Application
by the sponsors (Onyx Pharmaceuticals and Bayer Pharmaceuticals) to market the drug for metastatic kidney
cancer. It is expected that the FDA will approve sorafenib for treatment of patients with this disease.
This trial was one of the many performed at the University. In 2004, the UCCRC enrolled 1,170 patients in
160 cancer clinical trials, more than any other research facility in Illinois. These clinical trials enable cancer
patients to obtain promising cancer drugs before the FDA makes them available for general use.
In another trial, Dr. Wendy Stock and Olatoyosi Odenike, MD, demonstrated the potential of the experimental
drug depsipeptide, which alters the structure of our DNA, for treating patients suffering from acute myeloid
leukemia. Dr. Gini Fleming is investigating how to improve antihormone therapies for young women with
endocrine-responsive breast cancer. These women have a high risk for recurrence if not treated with antihormone
therapies.
Hedy Kindler, MD, Director of Gastrointestinal Oncology has investigated the effectiveness of combining the
cancer drug gemcitabine with the novel targeted agent bevacizumab to treat pancreatic cancer, one of the most
deadly malignancies. The success of this effort has lead to a national clinical trial of this regimen, also chaired
by Dr. Kindler, which could lead to FDA approval of this combination.
Dr. Koen Van Besien and the Leukemia-Lymphoma Transplantation Program are engaged in a clinical trial
of umbilical cord blood stem cell transplantation. The goal of this study is to increase access to bone marrow
transplantation treatment for patients without a compatible donor.
Mitchell C. Posner, MD, Chief of the Section of General Surgery
and Surgical Oncology, is collaborating with Irving Waxman, MD,
in clinical trials studying two novel endoscopic ultrasound guided
injection therapies for treatment of advanced pancreatic and esophageal
cancer. (An endoscope is an optical system for observing the inside of a
hollow organ or other body cavity.)
Thomas Gajewski, MD, PhD, and his team are engaged in clinical trials
examining the efficacy of vaccines for melanoma and other cancers.
Dr. Gajewski leads the Immunology and Cancer Program, which
focuses on the mechanisms of immune responses and immunotherapybased cancer trials. The program includes Dr. Albert Bendelac and his
investigators who study the role of natural killer T cells (NKT). At a
relatively young age, Dr. Bendelac made a discovery that caused a stir
among immunologists around the world. He characterized a type of T
cell, called a natural killer T cell, which is unusual for its targeting of
lipids instead of proteins. (Lipids are fats and a key component of cell
membranes.) In March 2005, The Howard Hughes Medical Institute
(HHMI) selected Drs. Bendelac and Milan Mrksich as new HHMI
investigators. Only 43 investigators nationwide earned this prestigious
honor in 2005.
Marcus Peter, PhD, is pursuing a provocative hypothesis suggesting that some types of chemotherapy may
actually promote the spread of cancer. Dr. Peter suspects that these therapies might reprogram “killer”
enzymes into ones that help tumor cells survive.
The Ben May Institute for Cancer Research
Dr. Peter is a member of the Ben May Institute for Cancer Research, which focuses on the basic research
that is fundamental to clinical advancements. Some of the UCCRC’s most fruitful collaborations involve
interactions between basic and clinical researchers. The scientists of the Institute are also members of the
UCCRC, and they have made fundamental discoveries that have helped clinical researchers enhance cancer
prevention, diagnosis and treatment. This year, the members from the Institute have expanded the boundaries
of knowledge of cellular dynamics and increased our knowledge of the processes that lead to cancer.
For example, Piers Nash, PhD, investigates how proteins work in combination to produce sophisticated
signals at the single cell level. Schooled in biochemistry, cell biology and bioinformatics, Dr. Nash and
his lab integrate these disciplines to probe the molecular mechanics of signal transduction that are so
intricately involved in malignancy. Dr. Nash is also utilizing computational tools to understand cellular
communication networks and is developing a massive, integrated database called Proteoscape, which will
make information on millions of proteins available to researchers worldwide.
Marsha Rosner, PhD, the Director of the Ben May Institute for Cancer Research and the Charles B. Huggins
Professor, also studies the intricate signaling processes that initiate cell growth. She has identified key molecules
that suppress or activate angiogenesis, which tumors use to develop blood vessels and obtain vital nutrients.
11
convergence |
The UCCRC examines ways to make existing therapies most effective for patients. Suzanne Conzen,
MD, discovered that hormones called glucocorticoids can initiate signaling mechanisms in breast cancer
cells that block their death and inhibit chemotherapy effectiveness. This is of concern because a synthetic
glucocorticoid, dexamethasone, is often administered to patients immediately prior to chemotherapy to
diminish chemotherapy side effects. Studies are ongoing to determine whether dexamethasone might,
therefore, result in the unwanted effect of reducing tumor response to chemotherapy. In a similar effort,
Drs. Wendy Stock and Stephen Kron are developing a test that will allow physicians to predict how Gleevec
will affect individual patients both in terms of toxicity and effectiveness.
Evaluating Existing Therapies
Her discovery will help scientists develop therapies that suppress angiogenesis and starve tumors. Dr. Rosner
has also found another molecule that is overactive in patients with head and neck cancer. Suppression of this
target can block the growth and proliferation of malignant cells.
Kay Macleod, PhD, studies the role of oxidative stress in cancer. Oxidative stress is the cellular damage caused
by free radicals, which are highly reactive chemicals that can promote the development of atherosclerosis, some
cancers, and other conditions. Antioxidants protect cells against these harmful effects, which is why they are
such a vital part of a healthy diet.
Sharing Expertise
These are just a few examples of how UCCRC members put their expertise to work producing invaluable
breakthroughs in our understanding of cancer and benefiting patients. Sharing this expertise is one of our
chief functions, and we have introduced numerous procedures for ensuring interaction between basic and
clinical researchers. For example, the UCCRC sponsors a monthly lecture series on translational inquiry. At
each meeting, a basic researcher and a clinical researcher present on a particular topic. These presentations and
the discussions that follow help bridge the gap between basic and clinical research.
This focus is also evident in the teaching of cancer biology. The Committee on Cancer Biology offers an
interdisciplinary program of studies leading to either a PhD degree in Cancer Biology or postdoctoral training
in preparation for research and teaching in this field. The program’s introductory graduate level course is
unique to the University of Chicago. It provides budding cancer biology researchers with a working knowledge
of the pathophysiology and treatment of human cancer so that the students can consider their basic research
projects in the context of current problems faced in detecting, preventing and treating human cancer.
Consequently, the course is taught by a team of instructors that includes a surgical pathologist, a basic scientist
who uses animal models to recapitulate human disease, and a physician-scientist. This year’s students are being
introduced to the intricacies of cancer biology by Amy Noffsinger, MD, who is an expert in cancer pathology;
Akira Imamoto, DDS, PhD, who uses genetically modified mice to study the mechanisms that control cell
growth; and Suzanne Conzen, MD, a medical oncologist whose laboratory studies molecular pathways in
breast cells that allow them to survive under conditions that would normally induce cell death. In contrast to
the traditional introductory PhD course in cancer biology, this unusual approach aims to give basic scientists
a foundation for their future experimental work by outlining the biological challenges faced by both the
clinicians who diagnose and treat cancer and the patients who experience cancer’s harmful effects.
Of course, the sharing of expertise goes far beyond the walls of
the University and the Hospitals. Thoracic oncology provides
an example of the many partnerships linking the UCCRC
with other institutions. Dr. Ravi Salgia is leading an ambitious
research program in lung cancer in collaboration with the
Roswell Park Cancer Institute (RPCI) in Buffalo, New York.
RPCI’s strengths, especially in the area of chemoprevention
and smoking cessation programs complement the UCCRC’s
best features. The University takes a strong leadership in clinical
cooperative groups that integrate national cancer clinical trial
efforts. It is the host institution for the Cancer and Leukemia
Group B (CALGB) clinical cooperative group chaired by Dr.
Richard Schilsky. The University is also an active member
of the Children’s Oncology Group (COG), Gynecologic
Oncology Group (GOG), and Radiation Therapy Oncology
Group (RTOG).
The members of the UCCRC represent a wealth of knowledge and expertise, which they bring enthusiastically
to the study of cancer. One cannot help but believe that Sir Isaac Newton would have embraced this culture of
collaboration and welcomed our disciplined and diligent investigators as colleagues.
Technology and Convergence
T
here is considerable evidence that cancers begin as single cells. These cells double at least 30 times before the
tumors are big enough to be detected clinically. By then, each tumor weighs approximately one gram and
contains one billion cells. (A gram equals .03 ounces.) Even at this miniscule size, the tumors may already
have evolved enough to metastasize and become deadly.
Consequently, some researchers are peering at cancer genesis at the most fundamental levels, and others
are developing advanced imaging techniques that help community clinicians to detect cancer earlier and
more effectively. Many of our researchers focus on the individual proteins and genes that regulate the life
cycle of each cell. Some of these microscopic substances regulate the signaling processes that tell cells to
proliferate, self-destruct, and perform other functions.
By combining their expertise with the latest in technology that allows them to work at the most
fundamental levels of biology, UCCRC scientists are able to analyze subtle changes in cells and organs,
look for molecular markers that suggest propensities to cancer, and diagnose malignancies earlier in their
development.
Investigating Molecular Structures
Dr. Greene’s lab, for example, uses X-ray crystallography to study 3D molecular structures in order
to understand more completely communication mechanisms that tell nuclear receptors, such as the
estrogen receptor, how to respond to hormones and SERMs (selective estrogen receptor modulators). His
observations have broad implications both for predicting receptor behavior and for the design of drugs
useful in the treatment and prevention of breast cancer. Sophisticated technology available at the Argonne
National Laboratory (ANL) facilitates Dr. Greene’s exploration of this miniature world.
The ANL has been an integral component of the University of Chicago since the Manhattan project
began in 1942. The Laboratory recently developed a Structural Biology Center built around the Advanced
Photon Source. Large enough to enclose a baseball park, this technology is capable of generating the most
brilliant X-ray beams in the nation. This technology allows Dr. Greene to gain insights critical to our
understanding of how hormones bind to their receptors to transmit signals and how we can modulate this
process to develop improved therapies.
13
convergence |
At the Molecular Level
Therefore, clinicians strive to diagnose and treat tumors as early in their development as possible or, even better,
prevent their genesis altogether. Some of the deadliest cancers (e.g. lung, liver, esophageal, ovarian, and pancreatic)
have low survival rates, in part, because they present few early symptoms and diagnosis often comes too late to
do any good. If we treat these tumors before they become established, the more effective we are likely to be in
extending patient survival and improving quality of life.
Advances in Imaging and Computer Aided Diagnosis
Technology also helps UCCRC researchers and clinicians detect cancers in patients well before overt
symptoms appear and tumor growth becomes widespread. They use artificial intelligence to develop
Computer Aided Diagnosis (CAD) strategies that offer radiologists a technological “second opinion” when
analyzing images from mammography screenings, ultrasound, computed tomography (CT), and magnetic
resonance imaging (MRI). This work effectively and efficiently improves the interpretation of images, greatly
reducing the incidence of missed cancers.
Samuel G. Armato III, PhD, and Heber MacMahon, MD, are
developing automated methods for comparing multiple chest
radiographs of the same patient. By accurately integrating a
series of chest radiographs over time, the techniques they are
perfecting enable radiologists to more easily and effectively
identify subtle, but critically significant, changes.
Breast cancer radiological screening is not always perfect, and,
at times, may result in false negatives and false positives. It can
be very difficult to determine if a spot on an image is a cancerous
lesion or something totally benign. This is particularly true of
younger women who typically have denser breasts. To meet this
challenge, Greg S. Karczmar, PhD, and Gillian Newstead, MB,
ChB, FACR, are exploring high spectral and spatial resolution
MRI. They are proving that this enhanced form of MRI is very
useful in early detection and staging of breast cancer.
Robert M. Nishikawa, PhD, and Maryellen Giger, PhD, are
evaluating breast tomosynthesis, which is a promising new
technology that produces two-dimensional slices through the
breast to create a three-dimensional image. In conventional, twodimensional mammography, overlapping breast tissues can either
obscure or mimic cancers. One of the drawbacks of this technique
is that the radiologist has more images to read. Drs. Nishikawa
and Giger are developing computer-aided detection methods to
assist radiologists read the large volume of image data.
Patients and physicians like Diane Yamada,
MD, benefit from advanced imaging
technologies. Dr. Yamada specializes in the
diagnosis and treatment of gynecologic
cancers. She is the principal investigator at
the University of Chicago for the Gynecologic
Oncology Group (GOG), a cooperative clinical
trials group supported by the National Cancer
Institute.
State-of-the-Art Surgery
Advanced technology is also playing a vital role in the operating room. Surgeons Gregory Zagaja, MD, and
Arieh Shalhav, MD, are refining robotic surgery techniques that provide much better outcomes for patients
than more conventional approaches. In the past three years, Drs. Zagaja and Shalhav have performed almost
400 robotic-assisted radical prostatectomies (excisions of part or all of the prostate gland) using the robotic
da Vinci surgical system, which provides improved visualization and decreased blood loss.
Since the two doctors have found that robotic surgery provides earlier and better recovery of both urinary
control and sexual function, the vast majority of prostate cancer surgeries done at the University of Chicago
are now performed using this approach.
Drs. Shalhav and Zagaja are bringing the benefits of sophisticated, state-of-the-art equipment directly to
patients. Like many of the researchers and clinicians at the University of Chicago, they are pushing new
technology to its limits and demonstrating the importance of expertise. Employing advanced technology
to full effectiveness begins with experienced, skilled scientists with the ability and creativity to take it to the
next level.
Michael Vannier, MD, a founder of the field of computational
anatomy and a leader in the development of three-dimensional
imaging, uses a 64-slice computed tomography scanner to
develop three-dimensional “movies” of a patient’s internal organs
without having to resort to invasive procedures. These images
study one patient’s kidneys from a variety of perspectives.
convergence |
15
Community and Convergence
T
he lab and the clinic are not the only domains for breakthrough cancer research. The research at the UCCRC
does not end at the boundaries of the University. This is where it often begins.
The UCCRC reaches far into local communities to engage the support and participation of the public, provide
programs that help people understand, avoid and deal with cancer, as well as gain information that helps us
investigate the underlying community dynamics that influence the distribution of malignancy. These efforts enable
us to advance a critical element of our mission: cancer control and prevention.
The Power of Prevention
The nation could cut cancer deaths in half if all Americans became determined to live healthier lives and
participate in screening programs using existing technologies. According to the American Cancer Society,
tobacco use will cause 168,140 cancer deaths nationwide this year, and another 190,090 deaths will be the
consequence of physical inactivity, poor nutrition, excess body weight, and other lifestyle choices.
Charles B. Brendler, MD, and his team investigated the relationship between dietary fat and prostate
cancer in Jamaican men who have the highest known incidence of prostate cancer in the world. They
have expanded this study to include Swedish men who also have a high incidence, and Japanese men who
have a very low incidence. This study holds the promise of providing helpful guidance encouraging men
to adjust their diets to prevent this malignancy, which will afflict 232,000 additional American men in
2005.
Dr. Andrea King’s laboratory is addressing the smoking problem head on. Her studies have demonstrated
a relationship between drinking alcohol and cigarette cravings. Furthermore, she has demonstrated that
these cravings intensify proportionately with increased levels of alcohol intake. In addition, Dr. King has
been involved in community-based smoking cessation programs, and she is examining the usefulness of a
medication (naltrexone) in helping people quit smoking.
Kyle Hogarth, MD, and his colleagues also offer smoking cessation programs to the community. They
focus on helping individuals at high risk for lung cancer, mesothelioma, and other malignancies.
Helping High-Risk Individuals
Serving people at risk is the goal of another program, the Cancer Risk Clinic. Olufunmilayo Olopade,
MBBS, directs the Clinic, which offers comprehensive risk assessment to people in the community. The
Clinic considers, in particular, the genetic risks associated with, breast, ovarian, colon, pancreatic, and
endometrial cancers. It also looks at other types of cancer and strives to treat patients from a comprehensive
perspective encompassing the specific needs of each patient or family member. Dr. Olopade’s creative
and visionary approaches to cancer prevention and treatment have gained worldwide recognition. The
MacArthur Foundation recently named her a MacArthur Fellow. This prestitigous award is known
informally as the “genius grant.”
Dr. Olopade is a member of the team of researchers, led by Sarah Gehlert, PhD, from diverse disciplines
that earned one of eight highly competitive grants to create a Center for Interdisciplinary Health Disparities
Research (CIHDR). The remain team members include Martha McClintock, PhD, Suzanne Conzen,
MD, Thomas Krausz, MD, FRCPath, Christopher Masi, MD, PhD, and Dr. Olopade are pursuing health
disparities research that analyzes differences in cancer incidence and development across various social and
ethnic groups. Based at the University’s Institute for Mind and Biology (Dr. McClintock, Director), the center
integrates the diverse expertise of social workers, psychologists, physicians and molecular geneticists to explore
the psychosocial and genetic causes of breast cancer in African-American women, including neighborhoods,
social isolation, stressors and medical co-morbidities.
The new Center is just one of the many initiatives designed to bring diverse disciplines together and increase
our impact on local communities. It complements the developing UCCRC “Cancer and the Social Sciences
Program,” mentioned in the “Vision and Convergence” section in this annual report. This effort will provide
cross-disciplinary research in technology assessment, genetics, risk assessment and intervention, health
outcomes, health disparities, quality of life, and medical ethics.
Information and Counseling for Patients and their Families
We also reach out to communities by providing valuable information and counseling. For example, the UCCRC
created the University of Chicago Cancer Resource Center to meet the cancer information needs of patients,
their friends and families, and the general public. Several years ago the American Cancer Society (ACS) joined
this effort, and the Center became part of the Society’s Patient Navigation Services,™ a nationwide effort
designed to ease the burden of cancer on patients and their families. This collaboration helps people learn
about cancer in all of its many manifestations, cope with its uncertainties, learn about ongoing cancer clinical
trials, get answers to their most troubling questions, and link with other worthwhile community resources.
Divya Jain of the UCCRC and Liz Ferrigno of the ACS manage the Center.
Education for the Community
Our numerous efforts to provide community physicians with the latest clinical information offer another
illustration of our close links with the community. A case in point is the effort of the Thoracic Oncology
Program, led by Ravi Salgia, MD, PhD, to educate doctors throughout the Chicago region on the latest
advances in cancer prevention, diagnosis and treatment. Teams of program members are presenting
the same lecture series at various locations throughout the region. Each meeting in the series focuses
on a particular malignancy. Dr. Salgia’s team discusses lung cancer, Dr. Kindler’s group presents on
mesothelioma, and head and neck cancer is the topic of the team led by Dr. Everett Vokes, MD, the John
E. Ultmann Professor of Medicine and Radiation and Cellular Oncology.
Chicago Mayor, Richard
M. Daley, Maggie Daley,
seven-time Tour de
France Champion Lance
Armstrong, and Cancer
Research Center Director
Michelle M. Le Beau, PhD,
at a rally to promote the
value of cancer clinical
trials.
Educating the community about the importance of cancer clinical trials was the goal of our sponsorship
of a health fair and rally to welcome to Chicago cancer survivor and seven-time Tour de France Champion
Lance Armstrong and the Bristol-Myers Squibb Tour of Hope™. The event, produced in collaboration
with the Robert H. Lurie Comprehensive Cancer Center of Northwestern University, attracted thousands
of people to the Chicago Loop. UCCRC Director Michelle M. Le Beau and other dignitaries, including
Armstrong and Chicago Mayor Richard Daley, spoke to the crowd about how clinical trials translate
discoveries made in the lab into promising new treatments and procedures that enhance patient care.
The UCCRC serves numerous groups of people and communities. It also derives invaluable support from
the people in surrounding neighborhoods and the entire region. Invariably, we depend on communities
of people from the patients who participate in life-saving clinical trials to the community leaders who
recognize the importance of our contribution to the region. One of the most important groups is the
community of volunteers and contributors who help make our work possible. This critical community
provides us with guidance, a voice in the region, and valuable funds that we leverage to attract financial
support from government agencies and cancer organizations. (More detailed information on this
community is available later in this report.)
Ultimately, the essence of the UCCRC is collaboration. At the heart of our organization is an abiding
faith in creative and fruitful interaction with individuals, colleagues, communities, patients, disciplines,
cancer organizations, government agencies, and other cancer centers and institutions of higher learning.
The University of Chicago Cancer Research Center
Thanks those who contributed from July 1, 2004 to June 30, 2005 to cancer and cancer-related programs
at the University of Chicago.
Rabbi Morris I. Esformes
Diamond Circle
$250,000 - $1,000,000
American Cancer Society
The Breast Cancer Research Foundation
Cancer Research Institute
Thomas J. Duckworth and
Connie Duckworth
Kadrovach-Duckworth Family Foundation
Susan G. Komen Breast Cancer Foundation
Leukemia & Lymphoma Society
UCCRF Women’s Board
Sapphire Circle
$100,000-$249,999
American Society of Clinical Oncology
Amererican Society for Therapeutic
Radiation Oncology Ed
Ben May Charitable Trust
Cancer & Leukemia Group B Foundation
The Entertainment Industry Foundation
Mr. and Mrs. Vincent Foglia
Genentech, Inc.
Sidney Kimmel Foundation
Joy McCann Foundation, Inc.
Mrs. Mary Jane O’Connor
William F. O’Connor Foundation
The Ovarian Cancer Research Fund, Inc.
Richardson, Patrick, Westbrook
& Brickman, L.L.C.
Mr. and Mrs. Gordon I. Segal
UCCRF Associates Board
The V Foundation
Ruby Circle
$50,000 - $99,999
American Association for Cancer Research, Inc.
AstraZeneca LP
Blum-Kovler Foundation, Inc.
Mrs. Joy Daugherty
Frank Consolidated Enterprises, Inc.
Mr. and Mrs. James S. Frank
Charles Hammersmith &
Carol Hammersmith Family Foundation
Leukemia Research Foundation, Inc.
Mr. Earl Meltzer
Pfizer U.S. Pharmaceuticals Group
Mr. Nicholas Kenneth Pontikes
Mr. George Rusu
UCCRF Auxiliary Board
Windy City Classic Foundation
$25,000 - $49,999
Amgen Inc.
Berlex Laboratories, Inc.
The Wendy Will Case Cancer Fund, Inc.
Harry F. & Elaine Chaddick Foundation Inc.
Children’s Cancer Research Fund
Citigroup Business Services
Mr. and Mrs. Marvin L. Conney
Mr. and Mrs. Jeffrey Diermeier
Enivar Charitable Fund
Mrs. Leonard S. Florsheim, Jr.
Goldman, Sachs & Company
Peter G. Horton Charitable Remainder
Annuity Trust
Klein Tools Charitable Foundation
The Lisa Klitzky Foundation
Ms. Eva B. Levi
Richard & Martha Melman Foundation
Alan M. Miller Foundation for Kidney
OfficeMax Inc.
Richemont North America, Inc.
Mr. Anthony Santacroce
Valda & Robert Svendsen Foundation
Gold Circle
$10,000 - $24,999
John W. Anderson Foundation
Banc of America, LLC
C N A Foundation
Mrs. Kathleen E. Chapski
Mr. and Mrs. Benjamin D. Chereskin
Chicago White Sox Charities, Inc.
CIBC World Market Corp.
Jordan L. Daniels, M.D.
Mr. L. M. de Kool
Brian Delanty Invitational
Driehaus Capital Management, Inc.
Mr. and Mrs. Richard L. Duchossois
Mr. Bruce William Duncan
Exelon Corporation
Fidelity Investments
Fidelity Charititable Gift Fund
Mr. and Mrs. Richard Gonzalez
The Albert Goodstein Family Foundation
Graff Diamonds (U.S.A.) Inc.
Grant High School Friends of UCCRF
Gulf Lumber Co.
Mr. and Mrs. Charles Harrold III
Illinois-Eastern Iowa Dist. of Kiwanis
Junior Cancer League
Charles S. Lazerwitz Charitable Trust
Mrs. Judy A. Lewis
David C. MacGregor, M.D.
Ms. Noreen McGuire
Mr. and Mrs. Bernard D. Meltzer
Ms. Rita Meltzer
Mercer Human Resource Consulting
J. P. Morgan Chase
Motorola, Inc.
Ortho Biotech Inc.
Mr. and Mrs. Bruce D. Ovitz
Pfizer Inc.
Prentiss Properties Acquisition Partners, L.P.
Michael Reese Health Trust
Riviera Country Club & Sports Center
Sara Lee Corporation
United Way of Metropolitan Chicago
Mr. James M. Weichselbaum
Mr. and Mrs. Richard M. Woldenberg
Mrs. Jane Woldenberg
Silver Circle
$5,000 - $9,999
Mr. Barry S. Alberts
Allstate Insurance Company
Ayco Charitable Foundation
Baxter International Inc.
Mr. and Mrs. Lawrence Benjamin
Mrs. Tybe Blink
Bristol-Myers Squibb Company
Estate of Lillian Z. Bronkhurst
Mr. and Mrs. Harris C. Brumfield
Mrs. Pauline M. Burelli
Mr. and Mrs. Richard C. Carr
Mr. Kevin J. Cogan
Credit Suisse First Boston LLC
Ms. Rebecca Davidson and
Mr. Richard Geddes
Mr. and Mrs. Ronald Duitsman
Peter and Virginia Foreman Foundation
The Gillette Company
GlaxoSmithKline
Mr. Michael C. Harris
Mr. Robert A. Helman
K-Five Construction Corporation
Mrs. Michael Klein
Ms. Carol Koterski Dugan
Mr. William J. Krug
Otto W. Lehmann Foundation
Mr. Laurence Lewis
Marlowe Corporation
Marsh USA Inc.
Mr. Marvin Miller
Modestus Bauer Foundation
Moneris Solutions Inc.
Neal, Murdock & Leroy, LLC
Mr. Stephen D. Nechtow
The Northern Trust Company
Organization Fund of the University
of Illinois at Urbana-Champaign
Ms. René C. Pasche
Mr. and Mrs. Robert K. Robinson
Mitchell Ross Childrens Cancer Fund
RST Memorial Cancer Foundation
Mr. and Mrs. Paul Rubschlager
Mrs. Ethelyn Schreiber
Schreiber Foundation for Cancer Research
Mr. and Mrs. Gerard Schulte
University of Illinois at Urbana-Champaign
$1,000,000 +
Platinum Circle
19
convergence |
Director’s
Leadership Circle
Bronze Circle
Founders
A & D Miller Foundation
Mr. and Mrs. William Adams IV
Alberto-Culver Company
Alternative Reproductive
Resources
Mr. and Mrs. J. Douglas Bacon
Bear Necessities Pediatric Cancer Fd.
Mr. and Mrs. Frank S. Brumfield
Mr. Donald J. Buchert
Mrs. Gregory Chun
Mr. and Mrs. Thomas L. Cox
Mr. and Mrs. Michael Crane
Mr. and Mrs. Andrew Da Miano
Mr. and Mrs. Thomas C. D’Aprile
Duk Young Foundation
Mr. and Mrs. Thomas Hardin
Mr. and Mrs. Steven Helms
Mr. Austin L. Hirsch and
Ms. Beth Gomberg-Hirsch
Mr. and Mrs. William Krug
Mr. Seymour Kulick
Mr. and Mrs. Andrew R. McGaan
Mr. and Mrs. Micharl McGuinnis
Mr. J. Clifford Moos
Mr. and Mrs. Robert Mueller
North Central Sect. Amer.
Urol. Assoc.
Mr. and Mrs. David Nuelle
Oppenheimer & Co.
Mr. Alan Oremus
Ms. Mary Bliss Packer
The Pittsburgh Foundation/
Patricia L. Knebel Memorial
Fund
Mr. and Mrs. Thomas Reusché
Ridgeview Industries
Ms. Susan M. Riley
Mr. and Mrs. Frank C. Schell III
The Ralph & Lois Silver
Foundation
Mr. Scott L. Stimpson
Mr. G. S. Stimpson
Mr. and Mrs. John Svoboda
Mrs. Lorraine Vandenbergh
Vanguard Charitable Endowment
Mr. and Mrs. Robert Von Halle
Ms. Joyce A. Wambold
Ms. Rosalind Wattel
Winston & Strawn LLP
Mr. and Mrs. James R.
Woldenberg
All Seasons Home
Improvements, Inc.
Aileen S. Andrew Foundation
Applied Medical
Mr. and Mrs. John Atchison
Bank of America, Illinois
Mr. and Mrs. James N. Bay, Jr.
Bays Corporation
Mr. and Mrs. Thomas Begel
William Blair & Company
Mr. and Mrs. Darcy R. Bonner
Mr. and Mrs. Don Borzak
Ms. Janna Bounds
Mr. and Mrs. James Brady
Mr. Stephen Brenner
John & Jacolyn Bucksbaum
Charitable Fund
Ms. Mary Burnstine and
Mr. Gerald Skoning
Mr. and Mrs. Michael J. Busch
Mr. and Mrs. William F. Cahill
Mr. Alvin Chereskin
Click Commerce, Inc.
Mr. and Mrs. Robert Conrad
ContiGroup Companies
Foundation
Mrs. Theresa A. Costello
Mr. and Mrs. Theodore K. Davis
Mr. and Mrs. David W.
Devonshire
Mr. and Mrs. John J. Dombek, Jr.
Mr. and Mrs. Richard F. Duffy
Mr. and Mrs. Wayne I. Elliott
Ms. Deborah M. Engel
Mrs. Fred Feinstein
Dr. and Mrs. Frank Fitch
Mr. and Mrs. Timothy Flood
Focus Surgery
Mr. and Mrs. David W. Fox, Jr.
Ms. Wende Fox and
Mr. James Lawson
Fox Lawson Management
Consulting Inc.
Mr. and Mrs. Louis E.
Freidheim, Jr.
Gastro Intestinal Research
Foundation
Mr. Ronald Goldman
Sheldon F. Good Family
Charitable Fdn.
Gorter Family Foundation
Dorothy & Freeman F. Gosden,
Jr. Foundation
Mr. Richard Gray
GRG Investment Partnership, LP
Mr. and Mrs. Raj Gupta
Hagopian Family Foundation
Mr. and Mrs. Brian Hahn
Mr. and Mrs. Thomas Hall
Mr. and Mrs. Robert Hartman
Mr. William H. Hartz, Jr.
Mr. and Mrs. William Hokin
Mr. Edward Hortick
International Foodservice
Manufacturers Association
$2,500 - $4,999
$1,000 - $2,499
Mr. Robert M. Janowiak
Mrs. Peggy O. Jones
Mr. David N. Jones
Ms. Mary E. Karnosky
Mr. and Mrs. Thomas Kennedy
Mr. and Mrs. Thomas Eric
Kilcollin
Mr. and Mrs. Donald A. King, Jr.
Kirby Sheet Metal Works, Inc.
Mr. John F. Kofler
Leonard & Ruth Kriser
Foundation
Mr. and Mrs. Gilbert W.
Kurschner, Jr.
L.E.K. Consulting LLC
Ms. Brian Latronico
Lavin Family Foundation
Mr. Alan A. Lazzara
Dr. Michelle M. Le Beau and
Dr. Robert Harwood
Mr. Roger J. Leyden
Lilly
Mr. John W. Luther
Ms. Elizabeth J. Martin
Marziani Enterprises, LLC
Mr. and Mrs. Roger McEniry
Mr. and Mrs. Patrick McGarvey
Dr. and Mrs. McKay McKinnon
Ms. Marsha Meskan
Mr. and Mrs. Edward J. Miller
Mrs. Karol J. Moller
Mudd Family Foundation
Mrs. Evelyn H. Nathanson
Mr. R. Gregory Neidballa /
Saddle & Cycle
Niamogue Foundation
Mr. Daniel E. O’Neil III
Orange Crush, LLC
Mr. and Mrs. Kirby Pearson
Mr. and Mrs. Robert Peterson
Astellas Pharma
Mr. and Mrs. Heber Pierce
Mr. Gerald Pilot
Mr. and Mrs. Gordon Lee Pollock
Mr. Thomas S. Postek
Mr. Roger H. Reckers
Mr. and Mrs. Paul J. Reilly
Mr. Evan B. Richards
Ms. Pamela M. Rojc
Mr. and Mrs. William Rose
Mr. James L. Rosenbloom
RTG - Prairie LLC
Mr. Scott Sauer
Mr. and Mrs. James H. Schink
Schumacher Capital LLC
Mr. and Mrs. Richard Scully
Mr. Lee S. Selander
Servall Company
Mr. and Mrs. Rex Sessions
Mr. Daniel M. Shepherd
Ms. Jean E. Sheridan
Mr. Sherwin Siegel
Mr. and Mrs. Robert W. Siegfried
Julie and Brian Simmons
Foundation
Mr. Lawrence Skatoff
Mr. John Stanfill
Stuart-Rodgers Ltd.
Ms. Cynthia J. Swartzloff
Dr. Richard Thometz
Mr. Samme Thompson
Oakleigh L. Thorne Fund
Mr. and Mrs. Barton G. Tretheway
Mr. and Mrs. Timothy H. Ubben
Mr. and Mrs. Gary Verhoeven
Ms. Nancy E. Voss
Dr. David Derwoei Wang
Mr. and Mrs. Keith Ward
Mr. and Mrs. William Wardrop
Mr. and Mrs. David C. Wenger
Mr. and Mrs. Michael Werner
Mr. and Mrs. J. Reading
Wilson, Jr.
Mr. and Mrs. Steven W. Wolf
Mr. Walter S. Wormser
Benefactors
Under $1,000
Mr. and Mrs. Gustavo O. Abello
Mr. and Mrs. John Ackerman
Ms. Barbara Stolberg Adelman
Mrs. Arthur M. Adler, Jr.
Ms. Joan G. Adler
Agape Foundation
Mr. and Mrs. Ronald J. Allen
Mr. and Mrs. William Allind
Mrs. Cheryl Allind
Allstadt Hardin Foundation
Mr. and Mrs. Richard Almeida
Almeida Family Foundation
Dr. and Mrs. Stephen Alport
Altair Advisers, LLC
Ms. Marilyn K. Alter
The Ambriance! Trust
Ms. Marilyn Amento
American Urological
Association Inc.
Mr. and Mrs. Keith B. Andersen
Mr. and Mrs. Jack Anderson
Ms. Betty-Alice Anderson
Mrs. Catherine R. Anderson
Mr. and Mrs. Craig Andrews
Mr. and Mrs. Everett W. Andrus
Ms. Jacqueline Annes
Mr. and Mrs. Larry Antonatos
Ms. Jean M. Antoniou
Aon Foundation
Ms. Helena B. Appleton
Mr. and Mrs. Frank E. Arnold
Ms. Kathy Arnold
Ms. Marcia Aronow & Family
Atlas Metal Industries, Inc.
Ms. Rita Atwood
Ms. Diane Patricia Atwood
Mr. Erwin K. Aulis and
Ms. Sharon V. Kristjanson
Aurora Foundation
Mr. Randy Aussenberg
Ms. Marta Holsman Babson
Mr. and Mrs. Kevin A. Connellan
Ms. Shirley E. Connors
Mr. Francis M. Connors
Law Office of Matthew J. Conti
Mr. and Mrs. Fred Cook
Mr. William H. Cooley, Jr.
Ms. Deborah Corbeil
Mrs. Deborah Sharko Corcoran
Mr. and Mrs. J. Patrick
Corsiglia, Jr.
Corus Bank, N.A.
Ms. Clea Costa
Mr. and Mrs. David Cox
Mr. and Mrs. Jeffrey Coyner
Ms. Mary T. Cozzens
Mr. and Mrs. John F. Cregan
Mr. James N. Criss
Mr. and Mrs. J. Michael Crouch
Arie and Ida Crown Memorial
Fund
Ms. Johanna Steinmetz
Cummings
The Honorable Barbara Currie
and Mr. David P. Currie
Mr. Thomas J. Curtin
Mr. and Mrs. Richard W. Cusack
Mr. and Mrs. Charles F. Custer
Mr. and Mrs. Walter J. Dabransky
Ms. Diane Dahl
Ms. Judith M. Daly
Mr. and Mrs. Thomas Dammeyer
Mr. and Mrs. Ryan M. D’Aprile
Ms. Lindsay M. D’Aprile
Mr. John B. David
Mrs. Robert M. David
Mr. and Mrs. Thomas Davis
Mrs. Lori Davis
Ms. Pamela S. Day
Ms. Susanna Decker
Ms. Deborah L. DeHaas
Mr. John A. Delaney
Delavan Community Chest
Senator James A. DeLeo
Deloitte Consulting LP
Delta Dental Plans Association
Mr. Norman E. Demb
Mr. and Mrs. Charles Demirjian
Ms. Jane M. Demler
Mr. and Mrs. John Derse
Mr. Herman J. Desmidt
Ms. Kathryn E. DeVaris
Mr. and Mrs. Raymond A.
Devorkin
Mr. and Mrs. W. Brinkley
Dickerson, Jr.
Mr. John N. Dietzen
Ms. Wanda C. Dill
Mr. Mark S. Disbrow
Mr. and Mrs. Nicholas A.
Dispensa
Diversified Food Sales System Inc.
Ms. Alice Feeney Doherty
M. Eileen Dolan, Ph.D.
Mr. Jay L. Dolgin
Mr. and Mrs. Richard S.
Donoghue, Jr.
Erin W. Donoghue
Mr. and Mrs. David Donovan
Ms. Colleen M. Donovan
Mr. and Mrs. Robert D. Douglass
Ms. Charenton Zelov Drake
Ms. Margaret A. Cremins
Mr. and Mrs. Keith Drollinger
Mr. and Mrs. Michael Dry
Mrs. Helene Dubow
Mr. George E. Duchossois
Ms. Mary Stephanie Duffin
Ms. Barbara Gaucher Duffy
Ms. Christine Dullum
Mr. and Mrs. John Dyer
The Ebersbach Family
Ms. Bernice C. Eckelkamp
Ms. Lynn Eikenbary
Ms. Maggie Smith Ekman
Mr. and Mrs. Ross D. Emmerman
Mr. and Mrs. John W. Empfield
Mr. and Mrs. John G. Encher
Ms. Carole Engberg
Ms. Alix Engel
Mr. Bill T. England
Ms. Judith J. Erfurth
Mrs. Kathy Even
Mr. and Mrs. Michael Even
Dr. Brian David Fagel
Ms. Maureen E. Fahey
Ms. Christine M. Fallon & Family
Dr. Ahmed A. E. Fareed
Ms. Kari Farkvam
Ms. Mary Ellen Faust
Mr. Jeffrey Feeney
Fellers Fixtures, Inc.
Mr. Carl Fellers
Mr. and Mrs. Gary Fencik
Ms. Diana S. Ferguson
Ferolito, Vultaggio & Sons
Dr. and Mrs. Anthony G. Finder
Fine Arts Engraving Company
Fine Designs LLC
Mr. and Mrs. Robert Finkel
Dr. Philip Fireman
Mr. and Mrs. H. Barney Firestone
First Data Western Union
Foundation
Ms. Margaret A. Fischer
Ms. Lois M. Fisher
Mr. and Mrs. Richard S. Fleisher
Ms. Kellianne Fleming
Mrs. Mary B. Flynn
Ms. Mary Therese Foley
Ms. Anne M. Forde
Dr. Harry A. Fozzard
Mr. and Mrs. Arthur E. Frame, Jr.
Ms. Georgia Frances
Ms. Olivia F. Frank
Ms. Susan Frank
Ms. Cynthia Frank
Mr. and Mrs. Philip Franklin
Ms. Christine C. Franklin
Ms. Debra Frederick
Ms. Lynn Fredrick
Mr. and Mrs. John E. Freund
Mr. and Mrs. Edward Freundlich
Mr. Charles H. Fries, Jr.
Mrs. Cindy R. Friman
Mr. and Mrs. Sidney Frisch
Mr. Henry J. Frisch
Mrs. Sheila M. Brennan-Johnson
Mr. and Mrs. Neil Brilliant
Mr. and Mrs. Daniel N. Brock
Mr. and Mrs. Brian J. Brodeur
Ms. Tracy Q. Brooker
Brookeridge Aero Associates, Inc.
Mr. Joseph W. Brosnan
Ms. Myra J. Brown
Mr. and Mrs. Murray Brown
Ms. Laura K. Brown
Mr. and Mrs. Allen Brown
Mrs. Merle P. Brown
Richard & Patricia Bruder
Foundation
Mr. and Mrs. Hardy Brumfield
Mr. John H. Bryan
Ms. Sheri A. Bucciferro
Mr. and Mrs DeWitt Buchanan
Mr. and Mrs. John A. Buck
Mr. Stuart D. Buck
Mr. and Mrs. Ronald Budil
Mr. and Mrs. Allan E. Bulley III
Mr. and Mrs. Irwin Buntman
Ms. Kim T. Burke
Mr. and Mrs. John Burnstine
Mr. William F. Cahill
Ms. Marie P. Calusinski
Campia Family Foundation
Ms. Kathleen A. Capone
Ms. Ellen Capua
Ms. Anne M. Carey
Mr. and Mrs. Douglas R. Carlson
Mr. and Mrs. Martin S. Carlson
Mrs. Diane B. Carlson
Ms. Theresa M. Carmody
Ms. Kathy L. Carney
Mr. Sean Michael Carney
Ms. Joanne Foltz Casey
Mr. Frank D. Cella
Ms. Shelby L. Chaden
Ms. Maria D. Chakos
Ms. Susanne K. Chakos and
Ms. Vickie D. Lukas
Mr. Steven M. Champlin
Mr. and Mrs. Alger B. Chapman
Mr. Philip J. Charleson
Mr. and Mrs. James Cherney
ChevronTexaco
Chicago Model Productions
Chicago Dowel Co., Inc.
Chicago Sun-Times
Childhood Leukemia Foundation
Mr. and Mrs. Edward E.
Christensen
Mr. and Mrs. Don Chudacoff
Ms. Gerri Cicchinelli
Mr. and Mrs. Charles F. Clarke III
Mr. and Mrs. Henrik Clausen
Ms. Laurie A. Cohen
Mr. William S. Cohen
Mrs. Inez Cohen
Mr. and Mrs. Tasso H. Coin
Ms. Elaine Stone Colburn
Mr. and Mrs. Neil Coleman
Ms. Julie A. Collins
Committee to Elect James A.
DeLeo
Ms. Dorothy Conger
21
convergence |
Mr. and Mrs. Nick Babson
Mr. Robert P. Baids
Ms. Suzanne M. Baker
Ms. Kim Baldo
Bank One Corporation
Bank of American United Way
Campaign
Mr. and Mrs. Chris Barber
Mr. and Mrs. James L. Barna
Mr. Alan M. Bartelstein
Ms. Maureen Connors Barton
Ms. Carol M. Bartucci
Ms. Margaret C. Bass
Mr. and Mrs. Roger Baum
Ms. Svea Herbst-Bayliss
Mrs. Salli Behrstock
Mr. and Mrs. William Belman
Mr. and Mrs. Thomas Belskis
Ms. M. Elizabeth Bennett
Mr. Eugene Bensinger and
Ms. Lynn Straus
Ms. Bonnie J. Benson
*Mrs. R. Ford Bentley
Mr. Peter J. H. Bentley
Ms. Robin Berg
Ms. Margaret Berger and
Mr. Michael Friedman
Berger, Newmark & Fenchel, P.C.
Dr. Earl O. Bergersen
Ms. Catherine Berkemeyer
Mr. and Mrs. Arthur Berman
Ms. Danielle Berns
Mr. Charles E. Bidwell
Mr. and Mrs. Richard C. Billett
Ms. Carol L. Billett
Ms. Mary Streckert Binder
Ms. Rosanna Bisulca
Mr. and Mrs. Randell S.
Blackburn
Marcia E. Blake, O.D.
Ms. Priscilla L. Blattner
Mr. and Mrs. Dan Blau
Mrs. Leah Block
Mrs. Harvey Block
Raymond S. Blunt & Company
Ms. Lisa J. Bock
Dr. and Mrs. Joseph Boggs
Mr. and Mrs. David Bomier
Mr. Thomas A. Bond
Mr. and Mrs. Scott Bondurant
Mr. Abraham Bookstein
Ms. Cheri L. Bornheim
Mr. and Mrs. Raymond H.
Bosworth
Ms. Mary T. Boyle
Ms. Sarah Josephine Boyle
Mr. Bruce C. Boynick
Ms. Colleen Kenney Bracco
Mr. and Mrs. Brian J. Brady
Mr. Brooke Brady
Ms. Donna Brady
Mr. James F. Brady, Jr.
Mr. Lawrence J. Brannian
Mr. Willard E. Bransky
Ms. Florence Stapler Braudy
Ms. June H. Braun-Leibowits
Ms. Melva J. Breitenstein
Ms. Arlene Brennan
Ms. Elise W. Frost
Mr. Ernest Fruehauf
Funkhouser Vegosen Liebman &
Dunn, Ltd.
Ms. Stella R. Furmanek
Barbara Vaughan Gabor, Ph.D.
Mr. and Mrs. Michael P. Galvin
Ms. Katie Gancer
Mr. Rocio Garcia
Mr. and Mrs. Donald F. Gardner
Ms. Sharon Garell
Mr. and Mrs. Vladimir Gastevich
Ms. Lili Gaubin
Ms. Karen M. Gaudio
Mr. and Mrs. James B. Gaw
Mrs. Martha F. Gearhart
Mr. and Mrs. Gary Gehlhoff
Mr. James I. Gelbort
Ms. Hope F. Geldes
Ms. Corinna L. Gelster
Geno’s Decorating, Inc.
Mr. Pasquale Genova
Ms. Andrea O. Gerow
Ms. Nancy A. Gerstadt
Ms. Sally D. Gibbs
Mrs. Kay F. Gillespie
Mr. Andrew S. Gold
Mr. and Mrs. Dennis K.
Goldman & Family
Ms. Bernadette Goldman
Goldman Sachs Philanthropy
Fund
Mr. and Mrs. Rodney L.
Goldstein
Mr. Leonard S. Goldstein
Mr. and Mrs. David Gomez, Jr.
Ms. Leah M. Gonzalez
Mr. and Mrs. James S. Gordon
Ms. Patricia M. Gorman
Gortho Ltd.
Ms. Karen L. Granda and Mr.
John Mrowiec
Mr. Herve Granjean
Ms. Carrie S. Grant
Ms. Patricia Grauf
Drs. Geoffrey and Marianne
Greene
Mrs. Ronald Greenspon
Mr. and Mrs. Larry Greenstein
Mr. Robert M. Green
Mr. and Mrs. David D. Gregg
Mr. Geoffrey F. Grossman
Mr. Jeffrey Charles Groulx
Mr. and Mrs. David Grumhaus, Jr.
Mr. Francis B. Gummere, Jr.
Mrs. Donna Gumminger
Mr. and Mrs. Laurence
Guthmann
Mr. and Mrs. Rodger A. Haga
Ms. Bernice L. Hajduk
Ms. Sheila Hammond
Ms. Suzanne Hammond and
Mr. Richard Leftwich
Ms. Rita Hanna
Ms. Jennifer L. Hansen
Ms. Georgia D. Harbin
Mr. and Mrs. John Hardin
Mr. and Mrs. Sheldon T. Harris
Mr. and Mrs. Kenneth A.
Harris, Jr.
Ms. Clarice A. Harris
Mr. David Hartsell and Ms.
Wendie Reece
Mr. Charles L. Haskell
Healing Heartaches
Mr. and Mrs. O. J. Heestand, Jr.
Ms. Svea Herbst-Bayliss
Hereau, Inc.
Mr. and Mrs. Bruce Heyman
Ms. Leslie Hickey
Hickey Foundation Inc.
Mr. Leo F. Hickman
J. Patrick Hieber, M.D.
Mr. Edgar L. Hiestand, Jr.
Mr. and Mrs. Larry Hill
Mr. James J. Hipp
Mrs. Ellen Hirsch
Mr. and Mrs. George Hirsh
Mr. Richard Henry Kleeman
Mr. and Mrs. Henry Hodge
Mr. and Mrs. Mark R. Hoffman
Mr. Robert T. Hofmann
Mr. Thomas Hoglund
Ms. Harriet T. Holderness
Mr. and Mrs. Willard Hollinger
Mr. Michael P. Hood
Mr. H.B. Hubachek, Jr.
Paul and Pandy Huff
Ms. Mardi B. Huffman
Mr. Richard E. Hulet
Mr. and Mrs. William P. Hummer
Ms. Patricia Cox Hunckler
Ms. Sharon Hunter
Hilarie and Justine Huscher
Mr. Leland E. Hutchinson and
Ms. Jean E. Perkins
Mrs. Barbara K. Hyman
Mr. Ralph Iacono
Mr. and Mrs. Peter Ianello
Ms. Donna Krier Ioppolo
Mr. and Mrs. Timothy Irons
Mr. and Mrs. Robert T. Isham, Jr.
Ms. Ruth J. Jackson
Mr. and Mrs. Daniel L. Jackson
Mr. and Mrs. Roy C. Jackson
Ms. Victoria Jackson
Mr. William L. Jackson
Mrs. Jacqueline J. Jackson
Ms. Phyllis Jacobellis
The Jaffee Foundation
Mr. and Mrs. Keith Jans
Mr. Eric L. Jensen
Ms. Anne K. Jensen
Jewish Federation of Metro
Chicago
Mr. and Mrs. Steven E. Johnson
Mr. and Mrs. Joseph C. Johnson
Mr. and Mrs. Wayne M. Johnson
Ms. Sheila M. Brennan-Johnson
Mr. Don Johnson
Mr. and Mrs. Richard Johnston
Mr. and Mrs. R. Stuart Johnstone
Dr. and Mrs. Burrill N. Josephs
Ms. Betty Z. Kahnweiler
Mr. David A. Kallick
Mrs. Gail Kamensky
Mr. and Mrs. Thomas G. Kamp
Mr. Jeffry W. Kamrow
Ms. Jean Kane
Mrs. Denis S. Karnosky
Mr. and Mrs. Robert F. Keeling
Ms. Carol W. Keenan
Ms. Mary L. Kelly
Ms. Kathryn Lynn Kemp
Ms. Dorothy L. Kern
Mrs. William T. Kernahan
Ms. Beverly Keseric
Mr. and Mrs. Roger W. Kieffer
Mr. and Mrs. William Kies
Ms. Linda Scherer Kimball
Mrs. Janet Kimmel
Mr. James King
Kirkland & Ellis Foundation
Drs. Diane and William Kleiber
Mr. and Mrs. Wayne Klein
Ms. Monica Davidson Klinke
Mr. Lawrence A. Klong
Mr. and Mrs. Ray Kluth
Rachel Kohler and Mark
Hoplamazian Charitable
Fund
Mr. and Mrs. Jerry Komas
Mr. and Mrs. Bernard Kompare
Mrs. Arthur Korach
Ms. Andrea Kott
Ms. Paula Kovarik
Ms. Ann Kowalsky and
Mr. Jerrold E. Salzman
Mr. Richard Koz
Mr. and Mrs. Harry M.
Kraemer, Jr.
Ms. Mary L. Krausfeldt
Dr. and Mrs. Norton Kristy
Mr. and Mrs. Donald F. Kroesch
Ms. Anne Kruchko
Ms. Gale J. Kryzak
Mr. John A. Kuhlman, Jr.
Mr. and Mrs. Greg Kunkel
Pat and Gib Kurschner
Mr. and Mrs. Phillip A.
Kurschner
Ms. Kelly Smith Kurschner
Ms. Sue Pauparas Kurz
The Lacina Family
Ms. Gale Lacina
Mr. and Mrs. Lucian LaGrange
Ms. Cathy Z. Lalich
Ms. Mary Patricia Landa
Mr. and Mrs. Marc D. Landsberg
Dr. Robert M. Lang
Jones Lang LaSalle Americas Inc.
Ms. Rachel Langtry
Jennifer and Joey Lansing
Ms. Lois A. Lapper
Mr. Hugh V. Larkin
Ms. Whitney Lasky
Mr. Jerry Latherow & Kersten
Stenson
Mr. William R. Lauer
Mr. and Mrs. Greg Lawton
Mr. and Mrs. Tom Leahy
Ms. June H. Braun-Leibowits
Mr. and Mrs. Peter Leibowitz
Mr. and Mrs. Frank A. Leone
Levenfeld Pearlstein LLC
Mr. Michael H. Levine
Elaine & Donald Levinson
Foundation
Mrs. Janet Lewis
Mr. and Mrs. David L.
Liebman III
Mr. David L. Liebman, Jr.
Mr. and Mrs. James Limper
Ms. Jacqueline Locola
Mr. Edward S. Loeb
Ms. Audrey W. Loeb
Mr. and Mrs. Robert Logan
Mrs. Robert Logan
Mr. William Lopatin
Mr. David S. Lott
Ms. Sophia Lotus
Mr. and Mrs. James Luebchow
Mr. and Mrs. Mathew Lunn
Mr. and Mrs. Michael Courtney
Lynch
Ms. Margaret A. Lyons
Mr. and Mrs. Saul Mackler
Dr. and Mrs. Amos Madanes
Mrs. Carl J. Madda
Ms. Felice M. Madda
Mr. and Mrs. William R. Madden
Ms. Christine Majkrzak
Mr. Stephen A. Malato
Mr. Barry Malkin and
Ms. Jodi Block
Mr. and Mrs. Barry J. Maloney
Mr. and Mrs. Richard T. Manak
Mr. Charles Manker
Ms. Joan Daniels Manley
Mr. and Mrs. Steve Manus
Mr. Michael A. Marchese
Marchese Educational Therapy
Mr. Paul R. Marchi
Mariani Enterprises, Inc.
Mr. James R. Marino
Mr. and Mrs. Raymond J.
Markman
Ms. Jill Marotta
Ms. Valerie K. Martinson
I. Martusciello
Mr. and Mrs. Ronald A. Marwitz
Dr. Alfred Marx
Ms. Evelyn Matasar
Mr. and Mrs. Kent Mathy
Mr. and Mrs. Robert W.
Matthews
Mr. and Mrs. David May
Ms. Florence B. Mayefsky
Mrs. Frank D. Mayer
Ms. Terese O. Mayer
Ms. Linda Mays
Ms. Maureen McAnney
Mr. and Mrs. Paul McCarthy
Dr. and Mrs. James B.
McCormick
Mr. Jerold K. McCoy
Ms. Patsy McCurdy
Mr. and Mrs. John McDermott
Mr. and Mrs. Michael L.
Pontarelli
Mr. and Mrs. Edward Pope
Portfolio, Inc.
Mr. and Mrs. R. Clifford Potter
Praecis Pharmaceuticals
PricewaterhouseCoopers LLP
Frederick H. Prince Trust/Prince
Charitable Trusts
Progressive Slovene Women of
America
Mr. and Mrs. Peter Prokopowicz
The Prudential Foundation
Mr. Kenneth R. Pyburn
Mrs. Diane L. Quackenbush
Mrs. Joan M. Quillman
Mr. Robert E. Rashkin
Ms. Susan M. Redden
The Research Team
Mr. John T. Rettaliata
Mr. and Mrs. J. Christopher
Reyes
Mrs. Anne Reyes
Mr. and Mrs. Tom Reynolds
Ms. Catherine C. Rhomberg
Mr. Roger Rhomberg
Ms. Catherine D. Rice
Ms. Dolores M. Richert
Ms. Suzanne S. Ridenour
Mr. Paul R. Ridenour, Sr.
Mr. Harold S. Ridenour
Mr. and Mrs. Harold D. Rider, Jr.
Ridgemoor Chapels, Inc.
Ms. Connie Riemer
Mr. Thomas F. Rochford
Ms. DeAnne Rogers
Ms. Dona C. Roper
Mrs. Maryann Rosenberg
Mr. Matthew Rosenshine
Drs. Marsha Rosner and
Robert Rosner
Ms. Marcia Roubik
Ms. Mary Roucka
Mr. and Mrs. Eric Rowley
Mr. and Mrs. Arlen D. Rubin
Mr. Albert B. Rubin
Ms. Adele Rubin
Mr. and Mrs. Howard Rudolf
Ms. Lori Runquist
Mr. and Mrs. Robert H. Rusher
Mr. Timothy M. Russell
Ms. Lauren E. Ryan
Mr. and Mrs. John Ryan
Ms. Noreen M. Ryan
Ms. Harriet E. Ryba
Mr. and Mrs. Jerrold M. Sadock
Mrs. Gail L. Sadock
Safeco Insurance Companies
Saleeby and Associates
Mr. Kenneth W. Sandberg
Ms. Ann M. Sanders
Mr. James Sarno
Mr. and Mrs. Robert Scarpelli
Scatchells Beef Stand Inc.
Mr. and Mrs. Marvin Schaefer
Mr. Robert P. Schaible
Mrs. Anna Mae Scherer
Ms. Pamela A. Scherzer
Mr. A. Bruce Schimberg
Mr. Gary Schinler
Mr. and Mrs. Robert L.
Schlossberg
Mr. and Mrs. William F. Schmidt
Ms. Nancy L. Schmidt
Mr. and Mrs. Frank P. Schorsch
Ms. Suzanne M. Schreck
Mr. and Mrs. Fred Schuler
Mr. and Mrs. Stephen Schuler
Ms. Jenny Schuler
Mrs. Dorothy A. Schulte
Ms. Paula M. Schumacker
Mr. and Mrs. William Schuman
The Schwab Fund for Charitable
Giving
The Alan & Roslyn Schwartz
Foundation
Mr. Robert I. Schwartz
Mr. Larry Schwartz
Ms. Trudy L. Schwartz
Mr. and Mrs. Richard D.
Schwartz
Alan & Roslyn Schwartz
Foundation
Mrs. Dorothy N. Schwartz
Mr. Scott C. Schweighauser and
Ms. Elizabeth J. Ellrodt
Mr. Michael J. Scully
Sean Patrick’s Salon
Ms. Eloise V. Searl
Mr. Scott Seder
Mr. and Mrs. Stephen P. Seder
Sedgwick / Detert, Moran &
Arnold
Mr. Verne P. Seehausen
Mr. and Mrs. Robin P. Selati
Mr. and Mrs. Louis C. Seno
Ms. Kay Settlif
Ms. Margaret A. Shanahan
Ms. Elizabeth A. Shannon
Mr. and Mrs. Laurence Jay
Shapiro
Mr. and Mrs. Jeffrey S. Sharp
Mrs. Ilene Shaw
Ms. Patricia M. Sheean
Ms. Elizabeth Condon Sheffer
Mr. William R. Shepard
Mr. and Mrs. Peter Sherman
Dr. and Mrs. Lowell Sherman
Ms. Muriel Horn Sherman
Ms. Wendy C. Sherman
Mr. Dale S. Sherman
Ms. Muriel Horn Sherman
Mr. Harry B. Sherrill
Mr. and Mrs. Martin Sherrod
Nancy & Stratford Shields
Ms. Barbara J. Shifley
Mr. and Mrs. Bud Sholl
Mr. and Mrs. Lloyd G. Shore
Mr. and Mrs. Paul Shukis
Mr. and Mrs. David Shute
Ms. Roberta R. Siegel
Siff Charitable Foundation
Mr. and Mrs. Jerry G. Silbert
Mr. and Mrs. Michael Silver
Marlo Good Nelson and
Joel Nelson
Ms. Patricia B. Newell
Mr. Jerome J. Niemann
Ms. Katherine E. Nikolai
Ms. Christina Nixon
Mrs. Di-Anne Norbut
Northern Trust Company
Charitable Trust
Mr. and Mrs. Lawrence Novak
Ms. Laura E. Nowicki
Ms. Rosemarie Nowicki
Ms. Elizabeth I. Nowicki
Nuveen Investments
Ms. Kathleen M. O’Brien
Mr. Jeffrey S. O’Dwyer
Mr. and Mrs. Cole Oehler
Mr. Victor B. Olason
Katherine L. Olson Charitable
Foundation
Ms. Elaine Olson
Oracle Corporation
Mr. and Mrs. Stuart Oran
Mr. and Mrs. James G. Orphan
Ms. Janis Lynn Oshensky
Ms. Cherilyn K. Ovca
Mrs. Donald R. Owen
Ms. Nana Owusu
Dr. Diane and Mr. Thomas Ozog
Ms. Jodiann Pacer
Mr. and Mrs. Eugene T. Paddock
Ms. Geraldine Page
Ms. Kathleen Palla
Mr. and Mrs. David Palmer
Mrs. Lynne A.J. Palmore
Mr. and Mrs. Carl J. Panek
Ms. Kathleen Park
Mr. and Mrs. G. Douglas
Patterson, Jr.
Mr. and Mrs. W. Andrew Patton
Arvydas Paulikas
Levenfeld Pearlstein
Mr. and Mrs. Marshall Peck
Ms. Georgy Ann Peluchiwski
Ms. Eileen Pembroke
Mr. and Mrs. Ian Pensinger
Ms. Jean E. Perkins
Mr. James Perlman
Mr. and Mrs. Richard Peske
Ms. Jane E. Petkus
Petty & Bielik Orthodontics, P.C.
Ms. Gail A. Petty
Mr. William Phipps
Ms. Minnie S. Phoenix
Ms. Amanda Pierce
Ms. Elaine Pietrini
Ms. Carol A. Pilliod
Ms. Lisa M. Pines
Ms. Sue Pinsky
Mr. and Mrs. Scott D. Pirkins
Mr. and Mrs. John J. Piva, Jr.
Ms. Mary A. Planek
Ms. Wendy Planek
PND Inc.
Mrs. Mac Pohn
Mrs. Rhonda Pohn
Mr. Eliaz Poleg
23
convergence |
Mr. and Mrs. James McDonough
Ms. Beryl McDonough
Mr. Thomas J. McFadden
Ms. Laura K. McGrath
Ms. Isabella McIlveen
Mr. and Mrs. James McNaughton
Mr. and Mrs. Corey B.
McPherrin
Ms. Evelyn McSherry
Mr. and Mrs. Elmer J. Mears
Ms. Cassandra M. Mellor
Ms. Rita Meltzer
Mr. and Mrs. Harold Merrill
Mr. and Mrs. Richard Merrill
Merrill Lynch
Ms. Gail E. Mesch
Mr. Burton C. Meyer
Mrs. Alan H. Mayer
Mr. and Mrs. Dieter B. Meyer
Mrs. Karen L. Meyer
Mr. and Mrs. David J. Meyers
Ms. Cari A. Meyers and
Mr. Ralph Sacks
Mary Elizabeth Meyers
Mr. Dan Michael
Mr. and Mrs. Robert Mignin
Mr. and Mrs. Edward Mikusch
Ms. Barbara Jo Miller
Ms. Barbara A. Miller
Mr. and Mrs. Milton Minkin
Mr. Sanford Mintz
Ms. Doreen W. Mitchell
Ms. Laura Davis Molk
Mr. and Mrs.Steven Molo
Ms. Patricia A. Monahan
Ms. Shauna M. Montgomery
Mr. and Mrs. William H.
Moore IV
Mr. and Mrs. James Moore
Mr. and Mrs. Joseph Moos
Mr. Joseph J. Morgan
Mr. Lawrence Morgan
Morgante-Wilson Architects, Ltd.
Mr. and Mrs. James Moriarity
Mr. and Mrs. Robert S. Morrison
Ms. Amy Fairbanks Morro
Mr. and Mrs. William Morrow
Mr. and Mrs. Richard A. Mortell
Mr. and Mrs. David Mosher
Mr. Sidney Moskowitz
Mrs. Melva J. Breitenstein
Dr. Douglas Mufuka
Mr. and Mrs. Wylie H. Mullen
Mr. Paul E. Mullen
Mr. and Mrs. Bruce Mumford
Mr. and Mrs. Robert S. Murley
Murphy, Meldroy, Melvin
Murphy
Ms. Melody Murphy
Ms. Michelle G. Nacker
Mr. Paul R. Napleton
Mr. Robert Napleton
Mr. and Mrs. James Nappo
National Philanthropic Trust
DAF
Navarro Negrete Properties, LLC
Mr. and Mrs. Scott Needham
Mrs. Gloria Silverman
Mr. Charles S. Simon
Mr. and Mrs. Brian D. Sims
Mr. and Mrs. Clive Sirkin
Ms. Kathleen Skapek
Mr. and Mrs. Gus P. Skizas
Ms. Carolyn D. Skok
Ms. Bernadette Skruck
Ms. Anne K. Smart
Ms. Susan K. Smith
Mr. Stephen L. Smith
Mr. James R. Sneider
Snelten, Inc.
Ms. Kathryn M. Soja
Ms. Lizz Sokolowski
Mr. and Mrs. Leonard H.
Solomon
Mr. Edward D. Somberg
Mr. and Mrs. Ronald T. Sorrow
Mrs. Cassie Spencer
Mr. John L. Spengler
Mr. and Mrs. Kenneth S.
Spielman
Mr. and Mrs. Robert E. Spitler
Mr. Robert Spitz
Mr. Gregory E. Spitzer
Mrs. Nancy M. Spohnholtz
Ms. Nancy Stankus
Ms. Corinne Myers Stransky
Mr. and Mrs. Jerry F. Staroba
Ms. Laura Staskiewicz
Mr. and Mrs. Richard J. Stefanski
Dr. and Mrs. John P. Steichen
Ms. Barbara Steinhauser
Mr. and Mrs. Taylor Stern
Mr. and Mrs. Bernard D. Sterner
Professors Carolyn and
Jack Stieber
Mr. and Mrs. Kevin L. Stoeckel
Ms. Margaret Stokes
Mr. and Mrs. William G. Stone
Ms. Susan Stone
Mrs. Rhonda L. Stone
Ms. Mary Strahota
Mrs. Edward Stransky
Ms. Sarah Stratton
Mr. Henry A. Straub
Ms. Marilyn K. Straus
Ms. Lynn Straus
Dr. John H. Strauss
Mr. and Mrs. Douglas A. Strubel
Mr. and Mrs. Alexander Stuart
Mr. Edward A. Suarez, Jr.
M/M Timothy Sullivan
Ms. Theresa B. Sullivan
Ms. Georgean Summers
Mr. Craig B. Sutter
Ms. Christine N. Sutton
Suzanne’s Hallmark Shop
Mr. and Mrs. John E. Swearingen
Ms. Janie Swenson and
Mr. William F. Lewis
Ms. Janie M. Swenson
Ms. Olga Swiontek
Ms. Carol W. Sykes
Mr. and Mrs. James Taich
Tap Pharmaceutical Products, Inc.
Mr. Frank Teacher
Mr. and Mrs. Earl Temkin
Ms. Terry J. Thiese
Mr. and Mrs. Robert Thomas
Mr. and Mrs. Michael Thomas
Mr. Joseph M. Thomas
Mr. and Mrs. Roger J. Thomson
Mrs. Constance R. Thomson
Thrivent Financial for Lutherans
Ms. Jennifer M. Tiernan
Ms. Christine M. Tierney
TMNA Wilwin Corporation
Mr. and Mrs. Stephen G.
Tomlinson
Mr. and Mrs. Leon Tonelson
Mr. and Mrs. John Totten
Mr. and Mrs. William H. Towle
Ms. Anita E. Trainor
Ms. Florence Tucek
Ms. Karen L. Turano
Mrs. Ruth E. Ultmann
Unisource Marketing Group
United Way/Crusade of Mercy
Mrs. Eileen C. Van Haren
Mr. and Mrs. Paul
Van Witzenburg
Mr. and Mrs. David Vander
Zanden
Ms. Louisa Vassileva and
Mr. Sean Carney
Mr. James Vetos
Mr. Edwin H. Vicich, Jr.
Mr. John Vinci
Ms. Faith A. Vitale
Drs. Tamara and Everett Vokes
Ms. Joyce M. Volpe
Ms. Elsa M. Volpe
Mr. Edward Vonesh
Mr. James F. Vonesh
Walsh Landscape
Construction, Inc.
The Walsh Family
Mrs. Patricia S. Walsh
Mrs. Margaret T. Walsh
Mr. and Mrs. Leonard Ward
Mr. Philip L. Watterson
Mr. Everett P. Weaver
Mr. and Mrs. Michael Weible
Ms. Kristen A. Weiler
Ralph Weiner & Associates LLC
(Employees)
Samuel Weinstein Family
Foundation
Weld-Rite Service, Inc.
Mr. and Mrs. Robert Werner
Mr. and Mrs. Donald Werner
Donald M. & Barbara Werner
Family Fdn.
Mr. and Mrs. Arthur F. Wernli
Wessel Family Foundation
Mr. and Mrs. Jeffrey A. Wheatley
Ms. Judy Wheatley
Mr. and Mrs. William White
Ms. Siobhan White
Ms. Lisa Fredian White
Ms. Janice M. White
Ms. Lisa Bowers White
Mr. Scott E. Whitsitt
Ms. Maralee Sabath Wicks
Ms. Christine G. Wieland
Ms. Kristen Wilcer
Mr. James A. Williams
Wine Spirit Distributors of Illinois
Charitable Foundation
Wippman, Gozum & Goldberg,
Ltd.
Mr. and Mrs. Paul Wisowaty
Mr. and Mrs. Arnold R. Wolff
Mr. and Mrs. Lee Wolfson
Ms. Carmen G. Woodring
Mr. Chester Wright
Mr. and Mrs. John Wyle
Ms. Trilbe Wynne
Mr. and Mrs. David Yeager
Mr. and Mrs. Mark A. Yeager
Mr. and Mrs. Charles G. Yorke
Mr. Jack D. Young, Jr.
Mr. and Mrs. Thomas M. Young
Ms. Laura Yunevich
Mrs. Suella Zajicek
Mrs. Sally Vander Zanden
Ms. Ann E. Ziegler
Mr. and Mrs. Jeffrey A. Zimmer
Mr. and Mrs. William
Zimmerman
Mr. and Mrs. Jerrold Zisook
Mr. and Mrs. Ron Zitko
Ms. Marjorie Zolla
Ms. Shelley E. Zuraw
Mr. and Mrs. Leon Zygmun
*Deceased
1. Left to right are Women’s Board 2004
Grand Auction Chairs Joanne Schell
and Lena Helms, Women’s Board
President Liz Adams and UCCRF
Director Mary Ellen Connellan.
2. Associate Board President Rita Brezina
and her husband Eric.
3. Past Auxiliary Board President Liz
Brandt is flanked by members Annette
Hickman (left) and Nancy Napalo
(right).
4. Auxiliary Board President
Margo Clavetti Frost with
Peter Donohue (left) and Bob
Hickman (right), husband
of Associate Board member
Annette Hickman.
5. Associate Board member
Taaron Silverstein and her
father Mark.
Boards and Auxiliaries
T
hroughout this annual report, we have discussed the value of collaboration in cancer research. No alliance is more
important than the partnership between the Cancer Research Center and its volunteers and donors. The University
of Chicago Cancer Research Foundation (UCCRF) and other supporting boards and auxiliaries form an essential
community of supporters. This community provides the seed funding that enables our members to pursue their most
innovative ideas and secure grants from governmental and non-profit organizations. These allies also provide important
links connecting us with the community and creating an ongoing dialogue. We depend on this interaction and treasure
the insightful guidance provided by these cherished allies.
The next several pages introduce you to these committees and their members and review some of the many ways they have
supported cancer research in FY 2004-2005.
Ruth Ann Gillis McGuinnis,
President
Mrs. William Adams IV, President
Liz Adams
John Atchison
James N. Bay, Jr.
Margaret Benjamin
Rita Brezina
Merle Cohen
Richard W. Cusack
John W. Derse, Jr.
Richard L. Duchossois
Thomas J. Duckworth
Ronald L. Duitsman
Nancy Florsheim
Wende L. Fox
Stanford J. Goldblatt
Charles P. Hammersmith, Jr.
Gwen Klein
John A Kuhlman, Jr.
Nancy Napalo
Lori Ovitz
Bruce Ovitz
Gloria Samuelson
Barton G. Tretheway
Honorary Trustees
Seymour A. Cohen
John D. Gray
William H. Hartz, Jr.
Leonard H. Lavin
J. Clifford Moos
Mrs. Alexander Anagnost
Mrs. Helena Appleton
Mrs. John R. Atchison
Allison Bacon
Mrs. James N. Bay
Margaret Benjamin
Mrs. Darcy Robert Bonner
Janna Bounds
Mrs. James Brady
Mrs. Harris C. Brumfield
Mrs. Bernard Burnstine
Mrs. Michael Joesph Busch
Mrs. Benjamin D. Chereskin
Mrs. Gregory Chun
Ms. Linda Burns Coleman
Mrs. Robert Conrad
Mrs. Fred Cook
Mrs. Thomas L. Cox
Mrs. Michael Crane
Mrs. J. Michael Crouch
Mrs. Richard W. Cusack
Mrs. Andrew Da Miano
Mrs. Thomas C. D’Aprile
Ms. Rebecca Davidson
Mrs. John Derse
Mrs. David W. Devonshire
Mrs. W. Brinkley Dickerson, Jr.
Ms. Suzette Flood
Ms. Susan Florence-Smith
Mrs. Fahey Flynn
Mrs. David W. Fox, Jr.
Mrs. Edward Gillette
Mrs. Thomas T. Hall
Mrs. Charles Harrold III
Mrs. Steven S. Helms
Lesli K. Henderson
Mrs. William J. Hokin
Mrs. Steven Edward Johnson
Mrs. R. Stuart Johnstone
Mrs. Thomas Eric Kilcollin
Mrs. Donald A. King, Jr.
Sustaining Members
Mrs. Bernard J. Kompare
Ms. Josephine Krug-Schulte
Kristine Kurschner
Karen L. Manzari
Ms. Amy Mazzolin
Mrs. Andrew McGaan
Robin Josephs McGarvey
Astrid A. McKinnon
Mrs. Edward J. Miller
Mrs. David Nuelle
Mrs. Stuart Oran
Ms. M. Bliss Packer
Mrs. Kirby Pearson
Mrs. Heber Pierce
Mrs. Gordon Lee Pollock
Mrs. Frederick Roe
Mrs. Frank C. Schell III
Mrs. James H. Schink
Mrs. Richard Scully
Barbara C. Sessions
Mrs. Barton Glenn Tretheway
Ms. Nancy Voss
Mrs. Keith Ward
Mrs. William Wardrop
Laura Werner
Ms. Alice Williams-Verhoeven
Mrs. Gail Kirk Bennett
Dr. Geraldine Balut Coleman
Mrs. Robert A. Conger
Mrs. Jeffrey Diermeier
Mrs. Gustav Horschke
Mrs. Donald Horwitz
Mrs. Robert Kimball
Mrs. Robert Kramer
Mrs. Donald Levinson
Mrs. Edward Liphardt
Mrs. Michael McGuinnis
Mrs. Robert Mignin
Mrs. R. Clifford Potter
Mrs. Sandra Reese-Stepke
Samantha Richardson
Mrs. Harry J. Smedley, Jr.
Mrs. John C. Stone
Mrs. Leon E. Zygmun
Honorary Members
Mrs. Walter E. Auch
Mrs. Wendy Becker-Payton
Mrs. Robert R. Bell
Mrs. Sharon Brix
Mrs. Seymour A. Cohen
Mrs. Alix Engel
Mrs. Leonard S. Florsheim, Jr.
Mrs. Maurice Goldblatt
Mrs. Margaret Laun-Knauf
Mrs. Arthur MacQuilkin
Ms. Cindy Reusché
Mrs. Charles W. Tallent
Mrs. Charles Walgreen III
The Women’s Board is a vital contributor to the pursuit
of the Cancer Research Center’s mission. This year the
members exceeded their record successes of past years
and provided the Center with a remarkable donation
of $635,000. This funding is being used for a variety of
purposes, which are discussed on the following page.
The Women’s
Board
25
convergence |
The Board
of Trustees
The Ben May Institute
for Cancer Research
Drug Discovery, Drug Development
and Advanced Instrumentation
Since 1951, the Ben May Institute has advanced cancer
research by addressing fundamental issues in the biological
sciences. The Women’s Board’s impressive history of
funding faculty recruitment and research in the Ben May
Institute has been critical to its success. The Board supported
the Institute’s recruitment of a scholar to model and make
predictions about the multitudes of complex interactions
and events that occur in a cell. People in business and
investors use similar models to anticipate changes in the
marketplace of the stock market. Having the ability to
model events in biology (to model how a cancer cell works,
for instance) is the wave of the future, and the Ben May
Institute intends to be at the forefront.
The Women’s Board has played an ongoing role in
the drug discovery process, which develops effective
therapies that take advantage of new knowledge of the
minute world of individual cells, genes, chromosomes
and proteins. Research at this level requires advanced
instrumentation and sophisticated libraries of chemical
compounds. The Women’s Board has supported the
purchase of equipment, which analyzes cancer cells and
provides detailed information about how these cells
respond to specific compounds. Such instruments are
essential for successful and full service drug discovery.
The Women’s Board has also helped the Cancer Research
Center purchase libraries of the compounds and small
molecules. Researchers are using new technology to
screen the compounds in these libraries to determine
which ones block the activity of cancer-related proteins.
Committee on Cancer Biology
The Women’s Board has long been a friend of the
Committee on Cancer Biology (CCB), which is one of the
premier cancer research degree-granting programs in the
nation. Dr. Geoffrey Greene chairs the committee. His
predecessor was Dr. Michelle M. Le Beau, the Director
of the University of Chicago Cancer Research Center.
Private funding from the Women’s Board ensures that
the Committee is able to attract and educate the most
promising students in the world. This year, the Women’s
Board is helping in the recruitment of young scholars who
will bring fresh perspective and enthusiasm to the pursuit
of the Center’s mission.
Human Tissue Procurement Facility
The Human Tissue Procurement (HTP) facility collects,
processes, and stores research-quality clinical material and
associated clinical information. These specimens are vital to
basic science, translational and clinical research projects. In
addition, the HTP also banks tissue for large institutional
initiatives. The facility requires highly trained staff to
ensure the viability of the tissue and provide investigators
with all the clinical and scientific information they need.
The Women’s Board has helped the core meet these critical
staffing needs.
cGMP Facility
The Women’s Board has been instrumental in the creation
and development of The University of Chicago Cellular
and Tissue Based Processing cGMP (current Good
Manufacturing Practices) Facility. The Board has been a
supporter since 1997 when the facility was first envisioned.
This resource provides investigators with a state-of-the-art
facility in which to prepare cell therapy products for phase I
and II clinical trials. The facility’s design meets clean room
and cGMP construction standards of a very high level.
Bioinformatics
Biomedical Informatics is the intersection of computer
and information sciences with biology and medicine. The
leadership of the Cancer Research Center has launched an
ambitious effort to systematically improve its capabilities
in biomedical informatics, which is enhancing research
across a broad spectrum of activities. The Cancer Research
and the Division of Biological Sciences Center recently
opened a biomedical informatics core facility which
serves the informatics needs of the faculty. The almost
overwhelming demand for these services demonstrates
the value of this facility to researchers. Funding from the
Women’s Board has helped fuel this successful program.
Clinical Informatics
The UCCRC is a national leader in cancer clinical trials.
These trials are a fundamental part of our fight against
cancer. The conduct of a clinical trial is subject to constant
and rigorous clinical, regulatory, and administrative
oversight. This oversight requires the principal investigator
to collaborate with many groups here and at multiple
institutions throughout each stage of the clinical trial
process. Ensuring the integrity of the research, complying
with government and sponsor requirements, and most
importantly, protecting the privacy and safety of our
patients involves many people managing much critical
and sensitive data. Funding from the Women Board has
played a significant role in the Cancer Research Center’s
successful efforts to improve the quality and efficiency of
clinical trial management and provide researchers with
improved, secure access to clinical trials information.
The Auxiliary Board
Sustaining Members
Margo Calvetti Frost,
President
Celeste Alcock
Cindy Alston
Tracy Bismonte
Susan Bondurant
Jackie Bossu
Elizabeth Brandt
Maggie Flanagan
Laurie Foster
Jan Gaines
Nancy Gupta
June Ghezzi
Annette Hickman
Terri Kingdom
Darlene Landsittel
Debbie Madlener
JoAnn McKibben
Andrea Montross Nancy Napalo
Karyn O’Connor
Jan Peterson
Cathy Pratt
Linda Russell
Tam Rustin
Laurie Shiel
Tierney Sharif
Ginger Stambaugh
Liz Williams
Christine Youngberg
Leigh Beith Shirley Bennett
Barbara Bridges
Anne Collins
Elizabeth Crawford
Ann Dougherty
Ethel Fox
Susan Fraley
Jane Hemmings
Jan Hetherington
Margaret Jacoby
Becky Kolleng
Joan Lancaster
Betty Ann Manganaro
Mary Marnell
Linda McCann
Jan McKnight
Mary O’Connell
Helen Panje
Mary Helen Ray
Laura Thomson
Patti Tyska
Mary Clare White
Honorary Members
Cheri Allen
Barbara Devlin
Barbara Grant
Carol Lynnes
Patsy McCurdy
Barbara Schmolze
Sharon Ubben
Founded in 1951 by Stephanie Howel, the Auxiliary Board raised $3,000 in its first year. The Board
was incorporated in 1959 as an official auxiliary of the UCCRF.
The Associate Board
Rita Brezina, President
Amy Will Brumfield
Tearle Calinog
Meghan DeRoma
Sadie Everett
Jim Foster
Amy Herron
Kristen Karczewski
Amanda Pierce
Dan Ryan
Elizabeth Ryan
Hayes Ryan
Lauren Ryan
Michael Ryan
Taaron Silverstein
Rob Soraparu
Justin Ullman
Nick Vogelzang
Although it is the UCCRF’s newest Board, the Associate Board has already
made significant contributions to advance cancer research and has helped the
University of Chicago maintain its reputation as a pioneer in the study and
treatment of malignant mesothelioma. In the 2004-2005 Fiscal Year, the
Board made a generous contribution of $140,000.
Mesothelioma Research
The Board supported mesothelioma research conducted by Hedy L. Kindler, MD, and
Ravi Salgia, MD, PhD. Malignant mesothelioma is a cancer affecting the lining of the
chest or abdomen.
Immunotherapy Research
The Board provided funds for immunotherapy research. Thomas F. Gajewski, MD,
PhD, is the leader of the UCCRC Immunology and Cancer Program, which studies
the body’s immune system and explores ways to enhance its ability to attack cancer.
The Junior Cancer League
Mrs. Kenneth Rabin, President
The League provided $21,000 to support Dr. Melvin L. Griem’s research in radiation oncology.
27
convergence |
In the 2004-2005 Fiscal Year, the Auxiliary Board provided $90,000 to support three cancer researchers: Amy
Peterson, MD; Karen M. Frank, MD, PhD; and Miriam B. Rodin, MD, PhD. Dr. Peterson develops new forms
of immunotherapy, Dr. Frank investigates both the immune system and the mechanisms of cancer development,
and Dr. Rodin studies the effects of cancer treatments on the memory, attention and thinking faculties of cancer
survivors.
Researcher Support
2004-2005 Financial Report
Income
UCCRF Beginning Balance July 1, 2004 $377,354
UCCRF Contributions
Unrestricted
Restricted Funds
669,105
Auxiliaries’ Income
Women’s Board
Auxiliary Board
Associates Board
Endowment Income
89,559
579,546
954,134
90,000
145,764
21,000
1,210,898
UCCRF Board of Trustees
Simon M. Shubitz 4,287
15,721
20,008
Total Income $1,900,011
Operating Expenses and Allocations
Operating Personnel
Services
Supplies
199,235
216,185
5,770
Allocations
Research & Faculty Support
Women’s Board
Auxiliary Board
Associates Board
Operating Expenses and Allocations $1,887,165
Ending Balance June 30, 2005 $390,200
UCCRC Financials 2004-05
Funding Agency
National Cancer Institute
30,055,120
Other National Institute of Health 36,884,537
American Cancer Society
1,333,528
National Science Foundation
504,625
Other Peer Reviewed
4,336,732
Industry Non Peer Reviewed
12,569,064
Other Non Peer Reviewed
18,974,412
Gifts/Endowments 11,086,901
115,744,919
421,190
579,975
635,000
90,000
140,000
21,000 1,465,975
Help Us Continue to Make a Difference
To learn more about cancer research at the University of Chicago and how
you can help our researchers pursue promising avenues of investigation that
would otherwise remain unexplored, please contact Mary Ellen Connellan,
Executive Director, University of Chicago Cancer Research Foundation, at
(773) 834-7490 or [email protected] A donation to the University of Chicago Cancer Research Foundation is an
investment in one of the nation’s leading facilities for scientific inquiry and
will help people here at home and around the world.
Donations by check may be made to:
The University of Chicago Cancer Research Foundation
5841 South Maryland Avenue, MC1140
Chicago, IL 60637
All gifts are tax deductible as provided by law.
The University of Chicago
Cancer Research Center
Michelle M. Le Beau, PhD
Director, the University of Chicago Cancer Research Center
Professor of Medicine and Human Genetics
Marcy A. List, PhD
Director for Administration
Scientific Director, Cancer Clinical Trials Office
Marsha R. Rosner, PhD
Deputy Director
Charles B. Huggins Professor and
Director, Ben May Institute for Cancer Research
Professor of Neurobiology, Pharmacology and Physiology
Everett E. Vokes, MD
Deputy Director
John E. Ultmann Professor of Medicine and
Director, Section of Hematology/Oncology
Professor of Radiation and Cellular Oncology
Geoffrey L. Greene, PhD
Associate Director for Basic Sciences, and Education
Virginia and D. K. Ludwig Professor and
Associate Director, Ben May Institute for Cancer Research
Professor of Biochemistry and Molecular Biology
Chair, Committee on Cancer Biology
Mark J. Ratain, MD
Associate Director for Clinical Sciences
Leon O. Jacobson Professor of Medicine
Chair, Committee on Clinical Pharmacology and Pharmacogenomics
Paul J. Butera, PhD
Director for Communications
Director, the University of Chicago Cancer Research Foundation
Jay Lewis
Director for Informatics and Technology
Maria Reyes
Director for Finance
Consuelo Skosey, RN, CCRP
Director for Clinical Research Operations
Technical Director, Cancer Clinical Trials Office
convergence
Editor:
Paul J. Butera, PhD
Design and Printing:
Pixel Print Graphics
©2005 The University of Chicago Cancer Research Center.
All rights reserved.
5841 South Maryland Avenue, MC1140, Chicago, IL 60637
www.uccrc.org

Vision | Expertise | Technology | Community

Transcription

Similar documents

CNTEAEDITION2Newsletter - Colts Neck Township Education

Important Dates First in Math - Clark

TOPICS No 27 - Trevallyn Primary School

newsletter no - Burwood Heights Primary School

Welcome to our 39 th academic year! - Fayetteville

TigerTales - Washington Co USD 108

Place Newsletter Name Here

www.tauntonschool.co.uk 26 April 2013 www.tauntonschool.co.uk

Summer Vacation! - Edwardsburg Intermediate School

Pages 26-30 - Springfield